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Background: Chronic lymphocytic leukemia is the most predominant leukemia of all the 
hematologic malignancies. It disproportionately afflicts older male Caucasians. It is 
classically considered a manageable but incurable disease. Consequent upon diagnosis, 
several treatment options are available, and the choice of which to use is determined to a 
large extent by the clinical, biological, and genetic manifestations of the disease.  
Up until 2014, gold standard for CLL treatment was chemoimmunotherapy-based. 
The advent of targeted therapy with agents that function at the gateway of dysregulated 
enzyme pathways, completely transformed the CLL treatment arena. The last decade has 
witnessed shifts in paradigm and rapidly changing treatment practices, attendant upon 
several new drug/treatment approvals. What type of shift in uptake and volume of the 
various classes of CLL agents has occurred due to these changes in pattern.?  
 vii 
Our study set to determine the shift in therapies of nine CLL therapies in the 
Veterans Health Administration System. It described the pharmacoepidemiology of 
traditional chemotherapies/chemoimmunotherapies (CT/CIT) and the novel agents, in the 
VHA CLL is a highly variable disease with important patient contributed factors that can 
affect outcome. Our study also focused on outcomes associated with these therapies, with 
a view to determining which are important influencers.  
This was a retrospective study of adults with CLL in the VHA from 10/01/2013 to 
5/31/2018. All were followed for at least 6 months. Data were extracted from the VHA 
electronic health record. Patients came from all 18 Veterans Integrated Service Networks, 
spanning all 50 states and US territories. Descriptive statistics were used to summarize the 
data, and chi and student-t-test to compare drug use, outcomes, and complications. 
Statistical significance was accepted at P<0.05.  
Our study showed that a total of 1,456 patients across all lines of therapy received 
at least one of nine CLL therapies of interest. Patients had a median age of 70 years (76% 
were 65+ and 24% were <65 years). A median age-adjusted Charlson comorbidity score 
of 5, and 9% had a history of exposure to Agent Orange. Within the period studied, CT/CIT 
accounted for about 73% of all treatments, while the novel agents use was 27%. Ibrutinib 
was predominantly used in first and second lines of therapy.  Ibrutinib use across all lines 
of therapy (LOTs) increased steadily while traditional CT/CIT use declined steadily over 
the study period. However, the traditional chemoimmunotherapies were predominantly 
used in patients under 65 years old, while ibrutinib was used more on those older than 74 
years.  A non-significant but higher incidence of diffuse large B cell lymphoma post-index 
 viii 
was higher in patients on CT/CIT than those on ibrutinib. Concomitant use of some 
medications increased the relative risk of death for both the novel agents and the CT/CITs 
but was seen more with the latter. 
In conclusion, novel agents are transforming the CLL treatment landscape, 
Traditional chemoimmunotherapies are still important in a subset of CLL patients. There 
has been a major shift in the treatment of CLL, with fast adoption of novel agents in the 
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OVERVIEW OF CHRONIC LYMPHOCYTIC LEUKEMIA 
What is chronic lymphocytic leukemia? 
  Leukemia, cancer of the white blood cells, is one of the most common types of 
blood cancer.1 It is myeloid or lymphoid in origin and comprises four biologically distinct 
subgroups of hematopoietic malignancies, viz. acute lymphoblastic leukemia, chronic 
lymphocytic leukemia, acute myeloid leukemia and chronic myeloid leukemia. It is acute 
when it shows up in the precursor cells and chronic when it manifests in the mature 
cells.2 Leukemia represents the 10th most common cause of cancer deaths and 11th most 
common cause of cancer incidence worldwide.3 According to the WHO classification of 
Tumors of the Hematopoietic and Lymphoid Tissues, chronic lymphocytic leukemia 
(CLL) is a low-grade lymphoproliferative neoplasm, with ≥5x109/L circulating clonal B-
cells that express CD5, CD19, CD20, CD23.4 CLL is the most prevalent leukemia in 
adults in the Western world, and it accounts for 25% to 30% of all leukemia types.5, 6 It is 
a blood and bone marrow disease where the body makes excessive amounts of 
lymphocytes that do not work properly because their DNA is damaged and cannot fight 
infections appropriately, negatively impacting the body’s immune system. It has been 
described as an “accumulation of functionally incompetent lymphocytes.”7 It is a slow-
growing disease and sufferers may be symptomless for several years. While some 
patients have a rapidly progressive disease that requires treatment, others may never 
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require therapy due to a very indolent clinical course of their disease. The disease 
typically affects older people and is rare in those aged < 50 years.8 Only about 6% of 
sufferers are aged below 50 years, while 25% are aged below 65 years at diagnosis.9 
Today CLL disease remains incurable, therefore treatment goal remains palliative, to 
slow down disease progression and prolong life. In recent years, due to large 
improvements in treatment options and the availability of targeted therapeutic and 
combination agents, 5-year survival has increased to over 66%, from 60% in the past 
decade, with over 80% of treated patients alive at 3 years.6 The economic burden of CLL 
in the United States is currently about $0.74 billion, projected to rise to $5.3 billion by 
the year 2025. This almost 600% increase in 6 years is mostly attributable to the entrance 
of the oral targeted therapies, which are considerably more expensive than the traditional 
therapies. 
Epidemiology of Chronic Lymphocytic Leukemia  
Globally, about 191,000 cases and 61,000 deaths due to CLL are recorded yearly. 
The incidence of CLL has been found to differ among different races and geographic 
locations, however, race rather than geography has been found to have more impact10 
Higher incidence rates are associated with countries in which human development index 
is high, including Canada, Australia, United States of America, and several European 
nations; whereas lowest incidence rates are found in West Africa and Asia.11 The 
incidence rate was 4.83/100,000 people in the United States from 1975 to 2014, with 
current estimates of about 20,000 new cases expected each year and an estimated 130,000 
people currently living with the disease.3 CLL is more common in whites than in blacks, 
 3 
very rare among Asians, and almost twice more likely to affect males than females. 12,13 
In 2019, 20720 new cases have so far been recorded in the United States, comprising 
12880 males and 7840 females.14 Improved health care and better lifestyles translate to an 
ever-aging population, and therefore, the median age at the diagnosis for CLL has 











Diagnosis and Prognosis in CLL 
Diagnosing CLL is often incidental, due to the nature of the disease to be 
asymptomatic for long periods. Patients present with an abnormally high white blood cell 
count (>5000 monoclonal lymphocytes/mm3), which may be accidentally discovered 
during routine blood count for a different condition. CLL is the most common cancer 
cause of unexplained high absolute lymphocyte count, although only a count of >5000/ 
mm3 may be indicative of CLL, the presence of greater than 5000/mm3 clonal B-cells in 
peripheral blood is required for diagnosis. Clonality of the B-cells confirmed by 
flowcytometry is required for establishing diagnosis. CD19, CD20, and CD23 are normal 
antigens expressed by B-lymphocyte, however, the presence of CD5, an antigen 
commonly expressed by T cells, but not B-cells is confirmatory of CLL.27 Other clinical 
presentations at diagnosis include lymphadenopathy which occurs in about 50%-90% of 
patients at time of diagnosis, cytopenias (autoimmune thrombocytopenia, autoimmune 
neutropenia, autoimmune hemolytic anemia) may be less frequently seen. Fever, night 
sweats, weight loss, and fatigue may not be present at this stage. Fingerprinting the 
lymphocytes to prove that they are all clonal and consistent with B-cell chronic 
lymphocytic leukemia is among the minimum requirements that must be met before a 
diagnosis of CLL is confirmed, in order to avoid exposing patients to misdiagnosis, 




CLL Staging Systems and Prediction Tools 
Two staging systems are commonly used for the characterization of CLL for 
prognosis and treatment purposes. The Rai staging system established in 1975, used more 
in the United States, was formerly a 5-stage system but was revised in 2016 into a risk 
stratified system that divides patients into low risk (Rai stage 0), intermediate risk (Rai 
stages I and II), and high risk (Rai stages III and IV).28 The stratification in the Rai 
system is based on lymphocytosis and other clinical features. The Binet system used 
more in Europe, was established in 1977 has three stages A, B, C. The classification is 
based more on number of involved areas, head and neck, axillae, liver spleen and groins 
as well as the presence of lymphadenopathy hemoglobin levels, and platelet levels.29 
Current developments in CLL therapy and molecular characteristics have rendered these 
two staging systems largely insufficient in identifying all risk groups in CLL.30  
A description of features of the Rai and Binet staging systems are summarized in Table 
1.1.  
STAGE CLINICAL FEATURES 
RAI System Binet System 
Low risk (stage 
0), A 
Lymphocytosis in the blood and 
bone marrow only 
Hb ≥ 10g/dl, Platelets ≥ 




risk (stages I 
and II), B 
Lymphocytosis + enlarged nodes 
at any site or enlarged spleen or 
enlarged liver  
As in stage A, in addition to ≥ 3 
lymph node involved. 
 
High risk 
(stages III and 
IV), C 
Lymphocytosis + Hb < 11g/dL or 
platelets < 100 x 109/L 
HB < 10g/dL or Platelets < 
100x109/L 
Table 1.1 Rai and Binet Staging Systems 
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Due to the heterogenic nature of CLL disease, both staging systems fall short in 
their ability to be predictive of disease progression because they do not consider other 
prognostic factors such as genetic aberrations that can also impact risk stratification and 
disease progression. For example, the clinical course of CLL in patients is more benign if 
they have a mutated immunoglobulin heavy-chain (IGHV), while 17p deletion is 
associated more with aggressive disease. 
Scientists have developed different prognostic models predictive of time to first 
treatment and prognosis.31 Some of these models have been found to help with improving 
clinical information useful in supporting the management of CLL, while the use of others 
has been limited by complexity and the need for information that are not easily available. 
The international prognostic index, a CLL prognostic scoring index (CLL-IPI), has been 
validated and shown to be a highly reproducible and effective prognostic tool for 
predicting OS. It is the most relevant prognostic tool currently.   It was developed using a 
weighted combination of five independent prognostic factors namely, age, clinical 
staging, IGHV mutational status, β2-microglobulin concentration and TP53 status. The 
tool stratified patients into four risk groups (low, intermediate, high, and very high), with 
distinctly different five year-overall survival.32 It proposes different treatment strategies 
for the different risk groups. 
CLL is a slow-growing disease, and about 25%-30% of patients will not require 
treatment at the time of diagnosis, while others will need some form of treatment.33 
Typically, patients in the Rai low risk stage or Binet A are usually carefully observed 
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without any treatment until rapid disease progression or they become symptomatic. The 
time to first treatment (TTFT) is an important parameter in newly diagnosed CLL 
patients because it can impact overall survival (OS). TTFT and treatment type are mainly 
determined by patient and disease-related variables, such as the aggressiveness of an 
individual’s disease, a patient’s functional status, co-morbidities, and the biology of the 
disease. Prognostic models, such as the CLL International Prognostic Index (CLL-IPI), 
that use a weighted combination of prognostic markers like age, clinical stage, TP53 
status and TP53 mutation, serum beta2 microglobulin, and IGHV mutation status, 
typically have been used to predict survival in CLL patients. The CLL-IPI stratifies 
patients into four distinct risk groups (low, intermediate, high and very high risk), with 
significantly different overall survival (OS), based on a scores index.  
The investigators who developed the CLL-IPI demonstrated that this type of 
prognostication index can be useful in predicting TTFT, including those newly diagnosed 
patients who are in the ‘watch & wait’ category. 32 They found that depending on the risk 
group, the TTFT differed. They were able to validate the number of patients that will 
commence CLL treatment for each year following diagnosis for up to 10 years post 
diagnosis in three cohorts. By year 5 of diagnosis, 10-25% of low risk, 46-71% of 
intermediate risk, 68-80% of high risk and 75-100% of very high-risk patients had 
initiated treatment. When analyzed in the cohort irrespective of risk group, 25-35% of the 
‘watch& wait’ patients commenced treatment by the fifth year of diagnosis. This analysis 
is supported by published studies reporting that 60-70% of previously untreated patients 
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with CLL with traditional clinical and laboratory features remained treatment-free at 60 
months of diagnosis.34  
 
Pharmacotherapy of Chronic Lymphocytic Leukemia 
CLL is regarded as a slow-growing and incurable disease for which some patients 
may never require treatment, while others eventually will need some form of therapy. 32,35 
Following the diagnosis of CLL in an individual, careful risk assessment is essential to 
select appropriate treatment. For most patients, their disease is early stage and they are 
not usually offered immediate treatment but managed with close observation and 
surveillance to identify when to initiate treatment upon disease progression. About 70% 
of such patients end up requiring treatment.36 Call Generally, there is no one-size-fits-all 
therapy; rather, the landscape is quite diverse with several options. Important factors in 
making treatment decisions are not limited to the clinical staging of the disease, and the 
evaluation of disease-specific prognostic biomarkers such as genetic anomalies, but also 
depend on age, comorbidities, physical capacity, nutritional status, cognitive capacity, 
ability to perform activities of daily living, social support and more recently, cost of 
treatment.37 Real-world data are still emerging from on-going studies as regards the 
treatment options in terms of tolerability, adverse effects, long term use, and disease 
outcome.38  
CLL therapies continue to evolve, leading to changing treatment paradigm. Three 
distinct phases in the advancement of CLL therapies can be clearly identified. For a long 
time, chlorambucil, with or without a steroid, was the only therapy available for CLL 
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patients who required treatment. Survival after treatment initiation was typically about 
five years, with complete remission in about 5%, and progression-free-survival of about 
one year. The first major therapeutic advancement was the purine analogues (fludarabine, 
pentostatin, and cladribine) in the 1980s. They were effective against chemotherapy-
resistant CLL.39,40 Next, was the addition of the anti-CD20 antibodies. Which began with 
a human-murine chimeric antibody, rituximab. The demonstration of modest clinical 
activity of rituximab, an antibody targeting the B-cell surface phosphoprotein CD20 as a 
single agent, marked the beginning of the immunochemotherapy era for CLL. It was 
found effective as a single agent in doses that are higher than are typically administered 
in other B-cell lymphomas.41 Presently, there are ample studies to demonstrate that the 
addition of an antibody to chemotherapy for CLL patients achieves a better outcome than 
with chemotherapy alone. Anti-CD20 antibodies are a group of compounds that are 
added to chemotherapy regimens to provide a patient with chemoimmunotherapy (CIT). 
The anti-CD 20 antibodies used in CLL therapy include rituximab, obinutuzumab, and 
ofatumumab. The combination of fludarabine, cyclophosphamide, and rituximab (FCR) 
was the first CIT regimen to prolong the OS of CLL patients. 43,29 Other combination 
treatments with these immunotherapies include: bendamustine plus rituximab (BR), 
pentostatin plus cyclophosphamide plus rituximab (PCR), ofatumumab plus chlorambucil 
(O+CB), obinutuzumab plus fludarabine plus cyclophosphamide (G+FC), obinutuzumab 
plus bendamustine (GB).443,0 Several studies have shown these to be treatment options 
that have improved outcomes for CLL patients to varying degrees.45,46 For a long time, 
FCR was the standard of care for first-line treatment of fit CLL patients, having been 
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shown effective in an MD Anderson Cancer Center (MDACC) study, with long-term 
outcomes of 72% complete response rate and 95% overall response rate. 47,48 BR is also 
another CIT that has a comparable outcome to FCR and is widely used in community 
settings. 49 In some cases, the immunotherapeutic agents have also been used as 
monotherapies as maintenance treatment regimens in some patients. Historically, 
therefore, we moved from single-agent therapy to treatment guidelines where 
chemotherapy, with the addition of an antibody, were the foremost regimens in the 
management of CLL. The goal of chemoimmunotherapy was disease eradication because 
their therapeutic mechanism targets the pathogenic cause of CLL by the elimination of 
the malignant B-cell clones, achieving high minimal residual disease (MRD) negativity 
and high clinical response rates. They are usually used in single or multiple cycles of 
treatment with a finite course or duration.  
As knowledge in the molecular biology and roles of prognostic factors in the 
clinical presentation of CLL continues to grow, novel targeted therapies; the B-cell 
receptor (BCR) inhibitors and B-cell lymphoma 2 (BCL-2) inhibitors that function at the 
checkpoints of dysregulated enzyme pathways have emerged. They have recently become 
the focus in CLL therapy, both as first-line treatments and in refractory/relapse cases. 
Ibrutinib, a Bruton tyrosine kinase inhibitor (BKI), was the first such agent to be 
approved by the FDA in 2013 for the treatment of mantle cell lymphoma and in February 
2014, its approval was expanded to include its use in treating CLL patients who have 
received at least one previous therapy.50,51 Others are idelalisib (phosphatidylinositol 3-
kinase inhibitor),52 and venetoclax, a Bcl-2 inhibitor,53,39 approved for patients with 
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relapse and del (17p). The use of ibrutinib is rapidly becoming standard of care as first-
line therapy for weaker older treatment-naive CLL patients,55,56 patients with poor-risk 
cytogenetics and decreasing fitness, as well as in relapsed cases. 57,58 The goal of therapy 
with these agents is disease control through sustained preservation of response and 
amelioration of disease symptoms. This way, they maintain enduring response and 
achieve long progression free survival (PFS). These agents are used to treat until 
progression or death occurs and their treatment course remains indefinite. 
With the advent of newer therapies, and the marked efficacy they have shown in 
clinical trials, the role of CIT is changing, with a generally downward trend. However, 
there is a need for cautious optimism, because the oldest of the targeted therapies, 
ibrutinib, has been used for less than ten years and scientists still have much to learn 
about this therapy. In addition, patients who are more physically fit and have better 
prognostic factors might still be good candidates for the chemoimmunotherapies. This is 
more so when one considers the adverse reactions, treatment discontinuation, drug 
resistance, high cost of treatment, and indefinite treatment regimens associated with the 
novel agents. 
Recently, CLL regimens based on combination strategies using agents from 
different classes and different mechanisms of action, are being evaluated and pushed into 
practice, in effort to improve depth of response, time-limited treatment duration, 
adherence, as well as reduce treatment failures, and improve patient outcomes. While 
combinations of CIT and targeted agent plus anti-CD20 antibodies have been in use for 
over two decades, double targeted agents with or without anti-CD20 antibodies are 
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becoming the next paradigm shift in CLL management. A pictorial summary of the time-
line of CLL therapies evolvement is shown in figure 1.2. 
 
 
Figure 1.2. Timeline highlighting historical therapeutic milestones and recent FDA 
approvals in CLL drug development. Ab=antibody, RR=relapsed refractory. 
Source: Mato et al 2015 (REF59) 
 
Mechanisms of action of CLL agents 
The importance of understanding the way a drug elicits its effect is crucial in 
making appropriate choice of agent and finds relevance in the sequencing of therapies in 
CLL, considering that most people will require a series of agents over time.60,61 It helps 
guide the decision whether to use these agents as sequential monotherapies or 
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combinations. Some of the anti-CLL agents have direct cytotoxic effect on the cancer 
cells and pathways, while others such as lenalidomide are immunomodulatory, and work 
at the level of the microenvironment and immune system. Currently, 4 to 5 major 
mechanisms are available for use in the drug treatment of CLL. Chlorambucil, 
bendamustine, and cyclophosphamide are alkylating agents that target and cause damage 
in cancer cells by inducing DNA inter strand crosslinks.  The nucleoside analogues 
(purine analogs) such as fludarabine, pentostatin, and cladribine inhibit enzymes relevant 
in DNA synthesis. Fludarabine inhibits the function of the DNA polymerase enzyme, 
primase, while pentostatin and cladribine inhibit adenosine deaminase required for DNA 
processing. Therefore, a combination of alkylating agents and purine analogues will 
induce DNA damage and inability of repair to occur, resulting in better killing effect on 
cancer cells. 62,63  
Anti-monoclonal CD20 antibodies are immunotherapeutic agents that target the 
overexpression of phosphoprotein CD20 on the surface of B-cell lymphoma cells. They 
attach to the surface of the cell by virtue of the CD20. Rituximab, Obinutuzumab, 
ofatumumab and Alemtuzumab (anti-CD52) have all been tried as maintenance 
chemotherapeutic agents alone or used in various combination regimens in CLL. 
Rituximab was the first of the anti CD20 to be approved by the FDA in 1998. Its modes 
of action consist of mainly cell-mediated cytotoxicity and direct apoptosis to a lesser 
extent.64 Obinutuzumab is a genetically engineered anti-CD20 that combines both anti 
CD20 and immunoglobulin monoclonal antibody. Upon binding to CD20, it also induces 
complement-mediated cell death and apoptosis which are both actin reorganization-
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dependent and lysosome-mediated.65 It has been shown to elicit the most potent response 
of the class. Ofatumumab, a humanized anti-CD20 targets a different epitope from 
rituximab for its action on complement-mediated cell-death and apoptosis. The anti-
CD20 agents oftentimes produce better overall survival and response as components of 
combination therapies with other class agents than when used as sequential 
monotherapies, because they are mostly effective for treating indolent lymphomas. 
Historically, they were used in combination regimens with the purine analogues and 
alkylating agents but are now in new use as combination agents with the targeted 
therapies.66,67  
Lenalidomide is an immunomodulator that induces immune effector T and NK 
cells as well as other cancer targets. It is a thalidomide analogue that down regulates 
cytokines thereby producing anti-angiogenic effects. Among its many anti-cancer 
mechanisms, is the upregulation of some anti-tumor genes and proteins leading to 
erythroid progenitor proliferation and cell adhesion in the cell microenvironment. Its 
optimal use in CLL management is still being evaluated due to its multiple mechanisms 
of action, toxicities and cross-toxicity with other agents. However, it shows some 
promising synergies with idelalisib and anti-CD20 agents 
The B-Cell Receptor (BCR) pathway is critical for B-cell development, survival, 
and migration. Ibrutinib, the first of the BCR-inhibitors to be approved for use in CLL, is 
an irreversible BTK inhibitor.68 It binds covalently to the cysteine 481 in the active site of 
the Bruton Kinase enzyme, this reduces further downstream signaling of other enzymes 
specific for the cellular responses to cytokines in the cancer pathway. This action hinders 
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the migration and proliferation of cancer cells.69 In other words, the BTK inhibitors 
inhibit the pathways for stimulus for the cell to live. Idelalisib and duvelisib are inhibitors 
of phosphatidylinositol 3-kinases (PI3K). Approved in 2014 by both the FDA and 
European Medicines Agency (EMA) for use in relapse/refractory CLL, idelalisib 
selectively inhibits PI3Kδ, while duvelisib inhibits isoforms PI3K-δ,γ.70  
The inhibition of PI3Kδ induces apoptosis in cell lines derived from B cell 
malignancies by promoting the inhibition of proliferation, chemotaxis, motility, adhesion, 
and survival of B cell. [58] Inhibition of both isoforms yields greater activity.71 
Venetoclax is an oral B cell lymphoma 2 (BCL2) inhibitor pro-apoptotic agent, targeting 
the antiapoptotic protein BCL-2.72 It is a BH3 mimetic that can cause immediate 
apoptosis of tumor cells by triggering and executing self-death in the cells. BH3 mimetics 
bind to the B-cell hydrophobic groove, inducing apoptosis and venetoclax can selectively 
target BCL2. Of all the novel agents, only venetoclax has been shown to produce deep, 
durable remissions.73  
CLL treatment strategies involving combinations of agents with different modes 
of action are rapidly gaining grounds in both practice and experimental settings. For 
example, the combination of ibrutinib plus venetoclax, two drugs with different 
mechanisms of action has recently been given initial license due to the synergistic action 
shown in efficacy by the doublet.  Preclinical studies in man and animal models show 
that BTK inhibitors increase the sensitivity of CLL cells to BCL-2 inhibitors.74,75   
Ibrutinib induces lymphocytosis that depletes the lymph nodes of tumor cells and 
mobilizes them into peripheral blood while venetoclax induces apoptosis that occurs 
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mainly in the blood and bone marrow, therefore both efficacies complement each 
other.76,74 Other combinatorial regimens are also being tested; BR + Obinutuzumab and 
venetoclax, where BR is expected to initially debulk the tumor, followed sequentially by 
time-limited maintenance regimen using Obinutuzumab+ venetoclax.77 Also, trial testing 
ventetoclax+ibrutinib and Obinutuzumab, alongside other four treatment regimens 
including the chemoimmunotherapy FCR/BR in physically fit patients is on-going.78  
Currently, response to treatment is assessed to be one of the following, complete 
remission, partial remission, stable disease, refractory disease and progression. Recently a 
new response criteria ‘minimal residual disease’ negativity has been added as an 
increasingly important response because recent studies have shown that MRD in patients 
who achieve complete or partial response can predict better progression free survival 
(PFS).79,80  
 
Review of critical literature on RCTs that established important management 
therapies. 
  Randomized controlled trials have often played key roles in determining safety 
and efficacy of outcomes of therapies. In CLL arena, many of such trials have focused on 
evaluating new ways of treating the disease and improving outcome. Many landmark 
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Other on-going RCTs of note include: 
FLAIR87 - In a phase 3 trial by the United Kingdom group (the FLAIR trial), 
treatment-naïve patients with CLL are randomized to 1 of 4 treatment arms: (1) FCR, (2) 
ibrutinib + rituximab, (3) ibrutinib, and (4) ibrutinib + venetoclax.  
CLL 1388 - In a phase 3 trial by the GCLLSG (the CLL13 trial), treatment-naïve patients 
with CLL are randomized to 1 of 4 treatment arms: (1) FCR/BR (based on age younger 
than or equal to 65 or older than 65 years), (2) venetoclax + obinutuzumab, (3) 
venetoclax + rituximab, and (4) venetoclax + ibrutinib + obinutuzumab.  
 
CLL Treatment Protocols and Guidelines 
CLL disease is considerably benign in the earlier years, becomes more 
progressive and resistant during the last few years. Typically, overall survival (OS) is 5-
10 years, within which time, patients may die of progressive disease or complications of 
therapy. However, a few patients with aggressive disease die within the first 2-3 years 
following diagnosis.28,89,45 It is important to note that CLL therapy is currently a moving 
target, with ever constantly changing scene. In the last eight years, development and 
standard of care for CLL has been rapidly evolving and official guidelines that define 
treatment guidelines, response to therapy, and clinical assessment are changing 
accordingly. The goal of therapy is to improve outcome by prolonging progression free 
survival and minimizing adverse effects of treatment. Current perspectives in treatment 
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paradigms revolve around continuous indefinite therapy and fixed course duration with 
sequential combination of agents. 
Changes in treatment guidelines have also been occurring as new knowledge on 
the disease and its treatment emerge. The National Comprehensive Cancer Network,90 the 
European Society for Medical Oncology Guidelines for CLL91 and the International 
workshop on CLL criteria are guidelines that are recently being used to define diagnosis, 
treatment and clinical response.92 
For low and intermediate risk patients with no symptomatic disease, a "wait and 
watch" approach is recommended. It has been shown that there is little or no benefit in 
initiating treatment early.93,94,95 Initiating therapy for the first time is left for active or 
symptomatic disease determined by the International Workshop on CLL criteria.92 When 
initiating therapy, treatment choice is guided by patient-based characteristics including 
comorbidities, age, and drug toxicity, this is the first line of therapy. Newly diagnosed 
patients with high-risk features of the disease can benefit from early intervention through 
clinical trials.96 It is important to note that CIT has no role where there is P53 gene 
aberration but will rather increase risk for complications. For younger and physically fit 
patients without TP53 (P53 aberration or del17p) anomaly, FCR is used as the standard 
of care, otherwise, ibrutinib is recommended. The CLL8 study demonstrated that 68% of 
patients treated with FCR were alive at 5.9 years of observation, and for patients with 
IGHV-mutated disease, the median progression-free survival exceeded 96 months at end 
of follow-up. Toxicities associated with FCR include neutropenias and increased risks of 
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infections. Substituting fludarabine with bendamustine or pentostatin, or reducing the 
dose of FCR, tend to be equally potent, but less toxic.81,97,98   
Chlorambucil with or without steroid is used mainly for elderly, frail patients, and 
with patients who have comorbidities, irrespective of age. Addition of anti-CD20 to 
chlorambucil improves OS when compared with chlorambucil alone. For treatment-naïve 
patients, in whom FCR might be considered inappropriate, ofatumumab plus 
chlorambucil is indicated. In recent times, the addition of obinutuzumab to chlorambucil 
is considered more adequate for elderly patients with comorbidities.83 It is also indicated 
in relapsed cases in patients who had previously received fludarabine-based therapy. 
Sometimes, the anti-CD20 can be extended as monotherapy for maintenance therapy, 
where the disease has become progressive. 99  
The newer therapies that target dysregulated pathways (ibrutinib, idelalisib, and 
venetoclax) have greatly increased treatment options for CLL, improved outcomes and 
consequently changed a lot of what guidelines existed prior to 2015. Ibrutinib is used as 
first line therapy in frail elderly patients, patients with 17p deletion (a more aggressive 
disease), patients with unmutated IGHV-status, and relapse cases. In situations where 
ibrutinib is not suitable due to the presence of certain comorbidities or adverse co-
medications, idelalisb plus rituximab, or venetoclax, have been shown to improve 
response rates, PFS, and OS.52 Ibrutinib is also largely used as initially approved, in 
relapsed / refractory CLL 55,58 It is now indicated in every CLL and widely prescribed. 
Venetoclax was initially approved for CLL patients with del17p, but currently it is the 
treatment of choice after ibrutinib failure as indicated by clinical trial that showed up to 
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70% response rate in patients who received venetoclax after ibrutinib.100 Recent approval 
of venetoclax+obinutuzumab for use in treatment naïve patients following the outcomes 
of the CLL14 clinical trial, brings it into first line use.101The targeted therapies currently 
available are orally administered and are taken for as long as they remain effective or 
interrupted by adverse effects, drug resistance, and emergent comorbidities. Ibrutinib has 
a high tendency to cause bleeding and atrial fibrillation; therefore, its use in patients with 
a history of cardiac disease and bleeding disorders is given careful consideration. 
Compromised immune systems and opportunistic infections may also limit the use of 
some of the newer therapies.  
Pharmacotherapeutic management of CLL disease continues to be the focus of 
research studies. Since the newer therapies hardly achieve complete remission in patients, 
they are taken until adverse effects or disease progression occludes their continued use. 
Recent studies have demonstrated promising results in looking to fashion therapies with 
individualized approach by combining the novel therapies with chemoimmunotherapies, 
especially in patients with severe disease. The principle in this approach is to initially 
reduce the high tumor burden in severe disease with a CIT agent, then apply novel agents 
and monoclonal antibodies for the induction and maintenance phases.102 Current practices 
seem to suggest that chemotherapy and chemoimmunotherapy is no longer the primary 
agent in CLL management for many patients, standard practice is now in favor of single-
agent treatments, doublets, and potentially, triplets of novel agents. Treatment protocols 
are now moving towards novel combinations as more knowledge become available, for 
example, the CLARITY trial that evaluated combination of BTK inhibitor (ibrutinib plus 
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a BCL-2 inhibitor (venetoclax) without anti-CD20 antibody.88 Similarly, the Eastern 
Cooperative Oncology Group (ECOG) is also conducting a three-drug combination 
regimen that adds Obinutuzumab to ibrutinib and venetoclax.103 
The future is still unfolding for CLL therapies—one that may see the use of 
current therapies in an approach that combines their different molecular mechanisms 
specifically customized to suit each patient's needs. 
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Drivers of Treatment Patterns and Outcomes in Real-world CLL Management  
Historically, the approach to the clinical management of CLL has been based 
more on risk stratification using the Rai and Binet staging which are dependent on CBC 
and lymphadenopathies. In recent times, algorithms that are more inclusive of prognostic 
molecular markers such as TP53 deletion, IGHV-mutation status, serum b2-
microglobulin, whose presence or absence impact disease severity, prognosis, and 
outcome, are increasingly being used to determine treatment.32 The interplay of these 
prognosticating factors with other host factors, such as comorbidities, age, and frailty can 
chart the course of the clinical management of CLL and influence treatment best 
practices. This has become more important since the introduction of the targeted 
therapies because cytogenetics, comorbidities and/or co-medications, weigh in more, in 
the decision, and the choice of which targeted agent to use. A plethora of treatment 
regimens (mono and combo regimens) are becoming more available for CLL 
management across all lines of therapy (LOT) and the novel agents have proven to offer 
better responses than CIT in the relapsed setting.47,104 
Predictably, patterns of care for CLL patients changed in response to the entrance 
and availability of the targeted agents due to the remarkable advances in improving 
clinical outcomes and durable responses they elicited in multiple CLL studies. 
Consequently, the last decade has witnessed shifts in paradigm with rapidly changing 
treatment practices and treatment guidelines, as well as several new drug/treatment 
approvals driven by these agents.105 Ibrutinib, the first of the novel agents to be approved, 
currently has 11 indications since its approval in 2013, including indications for treating 
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most patients in both first line and relapsed settings, as monotherapy and in combination 
with anti CD20 monoclonal antibody agents. Despite the impressive impact of the newer 
agents, unique toxicities and cost of treatment associated with them pose a challenge and 
continue to present significant differences between them and CIT.106 Furthermore, recent 
studies have noted differences between real-world data and the clinical trial reports, in the 
use of the targeted therapies.107  
What changes in uptake and volume of the various CLL therapeutic agents have 
occurred since the introduction of the targeted therapies? From 1999 to 2015, 
Bendamustine/Rituximab (BR), Fludarabine/Cyclophosphamide/Rituximab (FCR) and 
chlorambucil have each been reported to be the most common regimen used, followed by 
rituximab alone as the second most common regimen across all lines of therapy.108, 109,110 
It is notable that despite the existence of treatment guidelines, different studies conducted 
within similar time periods from various practice settings have reported differences in 
treatment uptake. Differences could arise due to other contributory factors besides age, 
patient’s functional health status, comorbidities, clinical and biological manifestations of 
the disease, which are significant considerations in the choice of therapy. Such factors 
include differences in practice settings, physician experience/choice, and factors related 
to patient-choice including quality of life, financial burden, and serious adverse effects. 
These have been shown to be tangible drivers of treatment patterns. 111,110,112 Patients 
prefer treatment regimens that offer longer PFS, however, they are willing to accept 
significant tradeoffs for it, to avoid serious adverse events.113  
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The novel agents are not cheap, cost of treatment is a potential issue for many 
patients. Recent studies have shown that the introduction of these therapies has 
substantially increased the cost of CLL treatment from both the payer and patient 
perspectives.25,65 Yearly cost of most of the novel agents such as ibrutinib is more than 
twice the annual income of an average American family with an out-of-pocket cost of 
about $36,000, compared to a CIT cost of only $325 in some cases.114 One study showed 
that per patient lifetime treatment cost increased from $147,000 to $604,000. In addition, 
the incremental cost-effectiveness ratio, when compared with chemoimmunotherapy, 
stands at $189,000 per Quality Adjusted Life Year (QALY).115 This clearly is a cost 
scenario that could potentially constitute a serious financial burden to most patients, 
which in turn, can lead to a poorer outcome in the real world, due to lack of affordability 
and consequent treatment discontinuation. Reports in literature indicate that higher out-
of-pocket costs for cancer treatments have been associated with non-compliance and lack 
of adherence among cancer patients.116,117 Therefore, despite the clinical activity and 
widespread use of these newer agents as frontline therapies, not all patients can use them.  
 
Treatment Complications and Adverse Effects 
Major safety concerns with CLL therapies as with other cancer therapies are 
treatment-related toxicities and adverse effects. It is critical in CLL therapy that patients 
are monitored for toxicities and adverse effects, so that they may be caught early and the 
necessary interventions made to forestall treatment disruptions and maximize outcomes, 
despite the challenging adverse effects. Common toxicities associated with the CIT such 
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as FCR are grade 3-4 neutropenias (about 34% of patients) and infections (about 25% of 
patients).43 To mitigate this level of toxicity, attempts to create less toxic but equally 
potent regimen led to the use of reduced doses of FCR, or replacement of fludarabine 
with pentostatin or cladribine or Bendamustine in the FCR combo. These were similarly 
toxic or less effective as FCR.118,119,120,121,81 The German CLL10 trial reported that 
although the FCR patients had longer median PFS than BR patients, there were equally 
more patients in this group that had severe grade neutropenias and infections.49 Ibrutinib 
has greater toxicities that differ from those of chemotherapies and these treatment-related 
toxicities have been associated with frequent discontinuation of the agent in real world, a 
phenomenon seen more with older (>80 years) and frail (worse ECOG performance) 
patients.122It has three times the risk of developing atrial fibrillation.123 while the use of 
PI3K inhibitors like idelalisib has been associated with immune-mediated adverse events 
like transaminitis, colitis, severe viral and pneumocystis infections, which seem to be  
more common when these agents are used in the first line setting. 124,125 It is 
recommended therefore that patients on these agents be given prophylaxis against 
pneumocystis jirovecii pneumonia (PJP) and be closely monitored for cytomegalovirus 
(CMV) reactivation, where there’s prior history of the infection.126,127 Venetoclax safety 
concern is related to its ability to elicit tumor lysis syndrome (TLS). 
 
Comorbidities in the treatment of CLL  
CLL primarily affects older people. The median age at diagnosis is about 72 years 
with over 70% of new cases being 65 years and above.9 Most elderly persons are living 
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with one or more comorbidities and some level of receding organ function.128 
Comorbidities play a major role in the selection of therapy in CLL management and 
literature reports that a high percentage of CLL patients have a comparatively greater 
comorbidity burden than their younger counterparts.129 The presence of these 
comorbidities may affect their biological status, rendering them ‘fit’ or ‘unfit’. Due to the 
fact that the elderly come with different ‘fit’ levels, the traditional approach of using 
chronological age for therapy selection may be flawed because patients of same age but 
with different fit status will most likely respond differently to a particular therapy. 
Therefore, it has become a recommended practice to assess biological rather than 
chronological age using the burden of comorbidities and ‘fit’ status.130  
Literature reports have given contrasting results on the impact of comorbidities on 
CLL outcomes.131 probably due to the different performance measurement indices used to 
determine the burden of comorbidities.132 Measures used to determine performance status 
include Eastern Cooperative Oncology Group133 and the Karnofski performance scale. 
Often used along is the estimation of comorbidity burden using Charlson comorbidity 
index,134 and Cumulative Illness Rating Scale.135 Classification of patients as fit or unfit is 
based on their renal function (unfit when the glomerular filtration rate is <70 mL/min) 
and their scores on the cumulative illness rating scale (unfit when the combined score is 
>6). Treatment regimens are thereafter adjusted accordingly.83 Fludarabine-based 
therapies considered standard of care until recently, is unsuitable for use in the older 
patients with coexisting conditions because it can cause myelosuppression and 
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infections.136 Recently, less toxic therapeutic regimens have shown good results in the 
elderly. 
 
Concurrent Medications in the treatment of CLL 
Studies have shown that at least 46% of patients on oral cancer therapy are at risk 
of potential drug-drug interactions (DDI) and 16% have documented harmful DDIs.137  
Another study reported that the frequency of at least one potential DDI occurring in 
cancer patients was as high as 63%, with 62% of them being major interactions with 
severe consequences.138 The prevalence of DDI involving tyrosine kinase inhibitors 
(TKIs) was found to be over 86% in a cohort of oncology patients, where about 45% 
were deemed potentially severe.139 About 93% of CLL patients exposed to treatment 
have at least one comorbidity and 89% have low to intermediate Charlson comorbidity 
index score.140 Pharmacovigilance during CLL therapy is an important consideration in 
treatment due to the existence of comorbidities in these patients, especially with the 
newer therapies. The study by Finnes et al reported that concurrent medication 
metabolized by CYP3A family of enzymes was found in at least 20% of CLL patients 
commencing treatment with ibrutinib.141 
Ibrutinib is extensively bio-transformed by CYP3A4, to a large extent, and 
CYP2D6, to a lesser degree. Other novel agents, CLL oral therapies, idelalisib, 
acalabrutinib and venetoclax are also similarly extensively metabolized by 
CYP3A4.142,143 The CYP3A4 isozyme is responsible for the metabolism of over 50% of 
all CYP450 metabolized drugs—about 60% of all prescribed drugs are metabolized 
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through CYP450. This is important because many of the drugs that are taken by older 
adults are potential enzyme modifiers, causing either inhibition or induction of the 
CYP450 enzyme. This can affect treatment response, efficacy, and toxicity including QT 
elongation. The rate of co-prescribing of drugs with potentials to affect TKIs was 
reported to range from 23%-74%.144 In addition, proton pump inhibitors have been shown 
to interact with tyrosine kinase inhibitors when concomitantly administered, affecting the 
systemic levels of the latter because the chronic acid suppression alters the acidic 
environment necessary for their absorption.145 Considering the significant impact of 
alterations in these enzyme metabolic pathways, and the fact that patients who were 
routinely on some of these medications were excluded from the clinical trials that 
established the efficacy of the therapies, it becomes necessary to evaluate the outcome of 
CLL therapies in the light of their concomitant use with medications for comorbidities 
and/or adverse effects. Medications for pain, acid reflux, anticoagulants, antiplatelets, 
antiarrhythmics, CYP3A4 inhibitors, and CYP3A4 inducers can be problematic when 
administered with CLL therapies.139,143,146-148  
 
Challenges with current CLL Management 
Challenges remain with CLL management as these molecular targets are 
increasingly integrated into current therapies. Many of the novel agents that have now 
become standards of care therapies are still under investigation and long-term outcomes 
and effectiveness are pending, seeing that the first of these agents has only been available 
for just about seven years. With the emerging protocols that combine novel agents and /or 
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anti-CD antibodies, better responses for a few years, definite treatment course have been 
shown, but benefit in OS is still lacking. Treatment for patients with high-risk disease and 
poor risk factors is still a challenge despite the availability of the novel agents’ combo 
regimens. CLL patients with P53 mutation especially are still inevitably relapsing despite 
the use of the novel protocols. Richter syndrome transforms the clinical course of CLL 
disease rapidly into an aggressive lymphoma with poor prognosis. Existing therapies 
continue to give suboptimal responses and clinical trials outside of intensive CIT remain 
the only viable option for inducing any appreciable remission.  
Clinical trials of new protocols and treatment regimens that are doublets and 
triplets continue to focus on patients younger than the median age of CLL patients in the 
US because there is concern about combined toxicities of the targeted agents in older 
patients. The CLARITY trial is for patients ≤70years of age, while the ECOG and other 
such large trials for patients older than 70 years have recently provided some insights in 
sequential/combination treatments with novel agents. 74,88 The issue of sequencing of 
therapies in order to avoid tumor lysis syndrome (TLS) is fast emerging because some of 
the novel agents such as venetoclax are able to kill enough cancer cells to induce TLS 
with its attendant consequences. Sequencing of therapies is needed to mitigate this 
concern, as is being evaluated in the ECOG trial. One of the current strategies for CLL 
treatment proposes achieving MRD negativity, which has been associated with deep 
remissions and possible ‘cure”. This strategy so far also involves sequencing of therapies 
starting with treatment induction with CIT, consolidation with novel agents and/ or stem 




The clinical management of CLL has been undergoing considerable 
transformation of its landscape since the last decade, leading to improved outcomes for 
patients with the disease. The plethora of treatments that exist have been made more 
diverse since the last decade. In one study, as many as seventeen different first line 
therapies in the pre-kinase era were documented.46 Treatments have moved from 
monotherapies to combination therapies with monoclonal antibodies, and more recently, 
to inhibitors of dysregulated pathways and their combinations. Literature reports on the 
clinical activity and increased use of the novel agents, as well as the toxicity of CT/CIT 
seem to suggest that the latter has little or no role in today’s CLL treatment.150 Several 
reports show that ibrutinib because of its improvement on treatment outcomes, toxicity 
profile and convenient oral formulation presently has taken over as the frontline therapy 
from regimens such as BR, FCR in many practice settings.151,109 Despite the wide use of 
these newer agents as frontline therapies, not all patients can use them.  The presence of 
unique adverse effects, cost and limitless treatment duration may constitute impediments 
to their effectiveness in real-world use. 
 
Some of the clinical trial results for the novel agents are yet to be duplicated in 
clinical practice settings. For example, an update from the RESONATE-2 trial, reported 
ibrutinib discontinuation rate of only 3%;152 however, real world data demonstrate that 
ibrutinib discontinuation rates generally range from 26% to 34%, and data from a recent 
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retrospective study reported an even higher discontinuation rate of 42% among relapsed 
patients.104,107,153-155, Real world data also demonstrate that the median PFS for ibrutinib 
was 35 months, a value that is much less than the 55 months observed in clinical trials. 
Furthermore, most clinical trial populations for CLL therapies are comprised of younger 
participants who can tolerate more aggressive chemotherapies and regimens, 
consequently yielding results that might not be representative of real-world effectiveness. 
The paucity of real-world evidence corroborating the effectiveness of these targeted 
therapies outside of clinical trials means that more research into the real-world outcomes 
of the treatment with the targeted therapies is needed. Additionally, while the tyrosine 
kinase inhibitors (TKIs) and the B-cell lymphoma 2 (BCL-2) inhibitors are 
revolutionizing CLL management, the pharmacoeconomic perspective of these therapies 
remains a concern. It is therefore pertinent that for CLL therapies, identifying and 
evaluating what works in the real life through clinical research is critical effort and 
knowledge that will advance progress towards improving outcomes for sufferers. 
The changing treatment landscape, increased use of the novel agents, and the 
toxicity of CT/CIT seem to suggest that the latter may be of limited use in today’s CLL 
treatment.156 However, the updated 2019 National Comprehensive Cancer Network 
Treatment Guideline for CLL recommends that CIT with FCR is still appropriate for the 
first-line treatment of younger CLL patients with mutated IGHV status because such 
patients are expected to achieve long PFS, maintenance-free remission and possible 
‘disease cure’. 73,90,157 Also, more recently, increased number of investigators are 
reporting reasons why the future may still have a role for anti-CD 20 antibody and CIT, 
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thus should not be abandoned due to their promising potential in inducing higher MRD 
negativity when combined in a ‘time-limited’ treatment course with the targeted 
therapies.158,85 What of cases where a patient fails all targeted therapies or presents with a 
tumor that requires rapid debulking? More recently, studies have suggested a future role 
for chemoimmunotherapies use as pretreatment to debulk or reduce tumor burden prior to 
treatment with the targeted therapies. The efficacy of some of such combinations and 
their comparative analyses with novel therapies are currently being assessed in clinical 
trials. 
Similarly, it is critical to evaluate the outcomes for these frontline conventional 
therapies in the light of the arrival of the novel therapies, because they may remain 
clinically relevant in many countries, as these novel agents are yet to be widely available 
globally. In countries such as the Netherlands, CIT remains the cornerstone of CLL 
therapy and their treatment guidelines clearly favor its use.85,159-161  
The rapidly increasing treatment options places a higher demand on clinical 
experience and evidence in choosing optimal therapy for a person diagnosed with CLL, 
regardless of the existence of treatment guidelines Recent real-world studies have 
observed treatment protocols outside of treatment guidelines in different practice 
settings.109 It is therefore important to understand treatment patterns, tolerability, and 
health outcomes and practices for CLL frontline treatments, especially with the advent of 
therapy with the novel agents. This is with the intention to determine the treatment 
practices that will aid optimal decisions in choice of effective therapies. 
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Finally, it is worthwhile to have a baseline upon which the impact of the entrance 
of the novel agents into CLL management can be tracked, measured and interpreted, to 
facilitate evaluation and understanding of CLL treatment patterns within the context of 
the changing treatment paradigms.  
What can we learn from records in a large database such as VHA? The proposed 
study aims to determine real world evidence regarding treatment outcomes in the national 
VHA population. Coincidentally, the U.S. veteran population offers the best setting that 
mirrors most CLL risk factors; 46% of veterans are age 65 years and older, 82% are 
white, 91% are male, and some have been exposed to Agent Orange in the Vietnam 
War.161 This makes the VA an ideal setting to study treatments and outcomes for patients 
with CLL. It will provide real-world evidence regarding CLL therapies in patients with 
the disease condition in the era of targeted therapy. This will be the largest study to date 
in this population. 
 
TRANSLATIONAL APPLICATION 
Translational Science (TS) is the science of focused research that aims to 
transform knowledge into interventions that improve patient outcomes. Sometimes, this is 
accomplished by minimizing risk, adverse effects, and costs. Interventions can be in the 
form of therapeutics, medical devices, diagnostics, processes and procedures, or 
behavioral changes. Randomized controlled trials (RCTs) remain the gold standard 
method of determining efficacy for therapeutics in healthcare, but they often do not 
reflect real world practices and patient outcomes. Real world patients are more diverse 
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than clinical trials allow, with varied manifestations of comorbidities, polypharmacy, and 
demographics. 
A properly designed study that uses robust clinical data obtained from real-life 
settings and/or records will yield real world evidence (RWE) that allow for improved 
interpretation of risks and benefits resulting from long-term use of a drug. This, in turn, 
can be used for informed decision-making that will improve outcomes. RWE is obtained 
from analyzing real‐world data (RWD). FDA defines RWE as “clinical evidence 
regarding the usage and potential benefits or risks of a medical product derived from 
analysis of RWD”. In other words, RWE is “evidence derived from RWD through the 
application of research methods”. It is not merely passively collected or anecdotal data, 
but rather results from careful study designs to assess the treatment effects on patient 
outcomes. Analysis of treatment outcomes may also help in determining the associations 
that wrap back around to inform and drive basic research. In other words, not only does 
RWD provide evidence that help translate scientific findings into the everyday care of 
patients in the general population, but it also helps translate the concerns of the patients, 
practitioners, and caregivers into scientific inquiry. 
Furthermore, observations from basic research may suggest larger clinical studies 
that may lead to discoveries that change or drive clinical practice. The discovery of CD5- 
or CD5+ monoclonal B lymphocytes in human peripheral blood in almost 10% of 
persons over 40 years of age with increasing amounts as age progresses, peaking at about 
50% in adults over 90 years, led to the use of monoclonal B cell lymphocytosis as a 
diagnostic parameter for CLL.162-65 Also, recent understanding of the biology of CLL led 
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to the discovery of small molecule inhibitors that target key mechanisms for CLL 
proliferation and survival with yet to-be- paralleled outcomes in patients, almost 
irrespective of their underlying genetic anomalies. The entrance of these small molecule 
inhibitors, the novel agents, into CLL therapy is revolutionizing treatment of patients; 
however, there is still challenges regarding their use in the real world. Ibrutinib was 
initially approved by the FDA for the treatment of relapsed CLL without TP53 deletion. 
However, data from real world use had led to its further approval as first line therapy in 
high-risk patients and somewhat healthy patients. On the other hand, its real-world use 
has shown that it is less well tolerated as previously predicted from clinical trials, with 
moderate to high discontinuation rates. Other knowledge gaps/uncertainties in the 
therapeutic management of CLL with the newer agents include the challenge of enduring 
unlimited number of years on the treatment, expense, toxicities, treatment failure arising 
from lack of adherence, drug resistance and polypharmacy issues such as drug-drug 
interactions. All of these can potentially limit the use of the newer agents. On the other 
hand, the chemoimmunotherapies such as FCR, FC, and BR have successfully been used 
as frontline therapies in CLL patients with different prognostic indices. 
Furthermore, the advent of the newer therapies seems to suggest that the use of 
chemoimmunotherapy may be approaching its end. Will CIT still be useful in CLL 
patients? For what category of patients? The clinical course of CLL is extremely variable, 
with many biological features impacting treatment choice, course, and prognosis. It is a 
disease condition where what works for individual patients differ quite a bit from 
guideline recommendations and clinical trial results.113 Analyzing real world outcomes 
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for CLL therapies based on patient-level data will facilitate appropriate risk-benefit 
analyses in advancing patient care by selecting therapeutic choices that result in better 
outcomes.  
CLL management is witnessing rapid transformations and transitions, these 
advances underscore the importance of translational medicine research. It is one of the 
most active areas in pathogenesis, diagnosis and treatment. CLL is a highly variable 
disease and research activities in the area research has helped provide the current 
understanding that combined assessment of clinical, genetic, biological, and physical 
factors are needed for optimization of therapy, contrary to the days of using only disease 
presentation. The treatment paradigms in the management of CLL currently lies in the 
development of therapies that aim to increase efficacy by causing deep remissions that 
prolong progression free survival and overall survival, reduce toxicities and provide 
convenient dosing options from both new and existing agents, based on the understanding 
of the pathology, immunology and disease biology. Such a feat is the hallmark of 
translational science. Translational research explores the most recent advances in the 
understanding of the pathogenesis and clinical behavior of the disease and how best to 
apply these insights to such a rapidly moving target. Studying CLL therapies in a large 
database, such as the VHA, through properly designed research studies, will potentially 
advance patient care by identifying the continued roles or otherwise of older CLL 
therapies, the optimal therapies for best patient outcome and the everchanging treatment 
landscape. Studies have demonstrated that patients value efficacy in selecting CLL 
therapies, but they will require essentially large gains in efficacy in order to offset the 
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disutility associated with risks of prevalence of adverse events as well as cost. Such 
information can be obtained in real-world clinical settings. Describing recent data on 
therapeutic regimens and outcomes of treatment for CLL as our study has done, helps to 
shed more light into understanding how to optimize therapy and current un-met needs, 









Aim 1. Describe treatment trends for nine select CLL therapies 2014 to 2018. 
Hypothesis A1.1: Chemotherapy-based therapies will be the most predominantly 
used CLL treatments for 1L, 2L, and 3L+ 
Hypothesis A1.2: Ibrutinib will be the most common CLL treatment for 1L, 2L 
and 3L+. 
Hypothesis A1.3: Novel treatments will exceed CT/CIT treatments in 1L, 2L, and 
3L+. 
Hypothesis A1.4: The uptake of CT/CIT will be more in the earlier years of the 










Strategy: Calculate the proportion of CLL patients using each of the select nine 
therapies for each line of therapy for each year and determine if there is a difference 
regarding their use and uptake. 
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Aim 2. Determine overall survival (OS) at 6 months for the nine select CLL treatments 
(1L only).  
Hypothesis A2.1: 6-month overall survival will be higher with ibrutinib than other 
therapies. 
Hypothesis A2.2: Overall survival rate will be higher with novel treatments than 








Aim 3. Determine overall survival as a timed outcome, from treatment initiation to 
death by any cause for the novel agents (NA) and the traditional therapies 
(CT/CIT), in the first line of therapy. 
Hypothesis 3: The probabilities of survival will be higher for the novel agents 






Strategy: Calculate the proportion of CLL patients alive at 6 months post treatment 
initiation for the nine select therapies, CT/CIT, and NA therapies. Determine if there 
is a difference in OS between the therapies, using ibrutinib as reference and CT/CIT 
vs NA, using the chi-square test. 
Strategy: Plot a survival analysis curve for patients on CT/CIT and NA therapies, 
determine and compare average (range) of survival in days using log rank test. 
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SECONDARY OBJECTIVES 
Aim 4. Determine time from diagnosis to treatment initiation (TTFT), time from 
initiation to discontinuation (TIDC), and time to next treatment (TTNT), for the 
nine select therapies. 
Hypothesis 4: Time to first treatment (TTFT), time from initial treatment to 
discontinuation (TIDC), and time-to-next treatment (TTNT), will be similar for all 
1L therapies. 
Hypothesis A4.2: Time to first treatment (TTFT), time from initial treatment to 
discontinuation (TIDC), and time-to-next treatment (TTNT), will be longer for 







Aim 5. Determine and compare health care facility utilization at 6 months (emergency 
room visits, urgent care visits, hospital admissions) for the nine select therapies. 
Hypothesis 5: A higher proportion of patients on CT/CIT will have emergency 
room visits, urgent care visits, and hospital admissions at 6 months than those on 
NA therapies. 
Calculate the mean ± standard deviation for each timed outcome for the nine select 
therapies, CT/CIT and NA therapies. Compare and determine if there are any 









Aim6. Determine and compare the pattern of select complications after 6 months of 
treatment in patients initiated on each of the nine select therapies. 
Hypothesis A6.1: There will be no difference in the pattern of select 
complications between the nine CLL therapies. 
Hypothesis A6.2: All the complications will be more prevalent in the CT/CIT 
therapies compared to the NA.  
Hypothesis A6.3: There will be no difference in the proportion of patients with 










Determine the specific proportions of patients who utilized each facility-based care 
at six months for the two groups of therapies. Compare each outcome in the two 
groups using chi square test. Test of significance is at P<0.05. 
Strategy: Determine overall complications post treatment initiation, and compare the 
trend among the nine select therapies, CT/CIT vs NA.   
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TERTIARY OBJECTIVES: 
Aim7. Describe and compare the uptake of 1L CT/CIT and NA therapies for black and 
white patients. 
Hypothesis 7: The black patients will lag behind in the uptake of novel therapies 








Aim8. Determine if CT/CIT and NA use is different for the age groups <65 years, 65-
74 years and >74 years. 









Strategy: Determine the uptake of all nine therapies in the 1L for years 2014 -2017, 
for black and white patient populations. Compare the proportions using chi square 
test. 
 
Strategy: Create three age-based groups (<65 years, 65-74 years and >74 years) for 
each of NA and CT/CIT. Determine the proportion of patients on CT/CIT and NA 
respectively for each age-group. 
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Aim9. Determine if FC/FCR/PCR and ibrutinib use and uptake is different for age 
groups (<65 years, 65-74 years and >74 years). 







Aim10: Compare use of FCR and ibrutinib for black and white patients in the different 
age groups.  
Hypothesis 10: There will be no difference in the use of FCR and ibrutinib for 







Aim11. Determine if 1L treatment patterns are different for patients with VA priority 
groups of 1, 2-6, and 7-8. 
Hypothesis 11.1: The use of all nine therapies will be similar for patients in all 
three VA priority groups. 
Strategy: Determine and compare (using chi-square test), the proportion of patients 
on FC/FCR/PCR and ibrutinib therapies for each age group. Compare the trends on 
a year by year basis. 
Strategy: Determine and compare (using chi-square test), the proportion of black 
and white patients on FCR and ibrutinib therapies for each age group and compare 
the differences in the use of both therapies.  
 49 
Hypothesis 11.2: The uptake of CT/CIT and NA therapies will be similar for 







Aim 12: Determine the relationship between Charlson Comorbidity Index score and 6 
months patient mortality and survival times. 
Hypothesis 12.1: Charlson Comorbidity Index score will be higher in patients 
who die than in those who survive. 
Hypothesis 12.2: Length of survival will be longer for the patients with lower 
charlson comorbidity index scores for CT/CIT and NA therapies.  
Hypothesis 12.2: Length of survival will be longer for the patients with lower 








Strategy: Compare the average Charlson Comorbidity index score for patients who die 
and those who survive within six months of treatment initiation. 
Classify patients in each treatment group into one of three CCI categories, stratified in 
accordance with Charlson age score, CCI 1-3 (Low severity), CCI 4-7 (Moderate - High 
severity) and CCI ≥ 8 (High severity). Compare the association between CCI scores and 
survival times in each therapy (CT/CIT and NA) and for NA vs CT/CIT, using the low 
CCI category as reference with student t-test. 
Strategy: Calculate the proportion of patients on the nine select therapies, CT/CIT 
and NA for each VA priority group using chi-square. Compare differences in 
uptake between the therapies, using VA group 1 as reference, and CT/CIT vs NA in 
each group using chi square test. 
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Aim 13: Determine the relationship between co-medications and patient mortality at 6 
months post treatment initiation. 
Hypothesis 13.1: The proportion of patients on select co-medications that are 
dead at 6 months will be same all nine therapies. 
Hypothesis 13.2: The proportion of patients on select co-medications that are 
dead or alive at 6 months will be same for CT/CIT and NA therapies. 
Hypothesis 13.3: Being on each of the select co-medications will increase the risk 





Strategy: Compare the percentage of patients on co-medication(s) who died and 
those who survived within six months of treatment initiation for nine select 
therapies, CT/CIT and NA. Determine the relative risk of death for each of the 
concomitant medications for each therapy and for CT/CIT and NA. 
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CHAPTER THREE 




This study is a retrospective cohort study of adult patients (at least 18 years old) 
with CLL in the VHA from 2014-2018. Historical data wase examined for up to 20 years 
prior to the study period.  
Data Source  
The VHA, with healthcare facilities in all 50 states, is the largest integrated health 
care system in the United States. It maintains an electronic medical record system, which 
includes administrative, clinical, laboratory, and pharmacy data repositories. These 
repositories include data from both hospital and clinic settings, providing visit-level 
information (VA MedSAS patient care datasets), patient-level (VA Master Vital Status 
and VA Mini Vital Status datasets), and VA Pharmacy Benefits Management Inpatient 
and Outpatient datasets. These data sets are linked together at patient level, using a 
unique patient identifier, making it possible for information for individual patients to be 
obtained across the datasets. Furthermore, the VHA system maintains a vital status file 
that enables investigators to determine patient mortality, even when it occurs outside the 
clinic or hospital. The study utilized these internal VHA databases for the study. 
Variables relevant to providing information for our study questions were created 
and used to build an analytic dataset for the study. Some of the variables of interest for 
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The study population consist of adult patients (at least 18 years old) with CLL 
diagnosis from VHA facilities across the United States. The sub-population with 
exposure to treatment with frontline therapies or novel agents for CLL between 2014-
2018 were further analyzed for different therapies and outcomes. 
Eligibility Criteria 
CLL patients (adults ≥18 years at date of CLL diagnosis) on treatment with a 
frontline agent (or their combinations) or novel agent for CLL in the patient identification 
period (index period) are assessed. ICD9 code 204.1x and ICD10 code 91.1x were used 
for the identification of patients. Patient selection based on the number of office visits 
and availability of EMR was used as criteria to establish accessing care from VA. 
Sample Size  
Preliminary counts of patients with CLL diagnosis within the study period in the 
VHA system yielded numbers greater than 26,000 CLL patients. The number of CLL 
patients on the select drug therapies will be determined as part of the study through actual 
counts in the database. Preliminary estimates suggest that approximately 4,000 patients 
will have received these therapies. This is a descriptive, population-based study, so the 
study sample comprises all patients in VHA system that meet the inclusion criteria—not 
just a subset of the population. 
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Figure 3.1 Attrition Diagram: Overview of Cohort determination 
Adults ≥ 18years at date of CLL diagnosis using ICD 9 and ICD 10 codes (204.1x 
and 91.1x) in VHA facilities nationwide.  
Patients with ≥ 6 months of follow-up  




 Study cohort  
Excluded  
Exposed to treatment between 10/01/2013 – 9/30/2017  
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Data Collection Approach 
Patient identification period (pre-index period) is from 2014-2018. Index date is 
defined as date of initiation of CLL related novel treatment (order date for oral 
medications or treatment administration date for IV regimens). The follow-up period 
allows patients to be followed for a minimum of 6 months post-index. Patients will be 
followed until the last VA visit, loss to follow-up, a record of death, or end of the study 
period, whichever occurs earlier. SAS association rules and coding algorithms were used 
to create variables that represent the nine select therapies groupings. 
Study Time Period 
Study period: 2014- 2018 (including 6 months of follow up) 
Patient identification period (index period): Oct 1, 2013-Sept 30, 2017 
Index date: date of initiation of CLL related systemic treatment (order date for 
oral medications or treatment administration date for IV regimens) 
Pre-index period (baseline/observation period): all data available before index 
date since 10/01/1993 
Follow-up period: allows patients to be followed for a minimum of 6 months 
post-index. Patients were followed until last VA visit, loss to follow-up, record of death, 
or end of study period, whichever occurred earlier. 
 
Exposures and Treatment Patterns: 
The study drugs selected from FDA approved drugs for the treatment of CLL are 
listed in table 3.1. CLL patients with a frontline agent and/or novel agent for CLL in the 
 55 
patient identification period (index period) were assessed. Although CLL treatment is one 
of the fastest changing oncology treatment landscape, we have included the most 
innovative and clinically relevant treatment options for CLL pharmacotherapy as at the 
time of the study development. The drugs were assessed from the database using three 
identifiers, generic name, National drug code (NDC) and current procedural terminology 
/ Healthcare common procedure coding system (CPT/HCPCS).166,167  
 





Fludarabine Phosphate Fludara, Oforta 





































Immunomodulatory Lenalidomide Revlimid 
 




For the purpose of the study, clinically relevant CLL monotherapies, 
chemotherapies, chemoimmunotherapies (chemotherapy + anti CD20 monoclonal 
antibody), and novel therapies were identified in accordance with NCCN treatment 
guidelines and clinical judgement.90 They were further categorized into nine select 
therapy groups, as defined in table 2. Outcomes and treatment patterns were evaluated 
based on these select therapies and three lines of therapy, first line (1L), second line (2L), 




Table 3.2. Definition of Nine Select therapies. 
 
Treatment Root (OR) Combination 
(AND) 
Exclude (NOT) 
BR bendamustine rituximab fludarabine, cyclophosphamide, 
pentostatin, ibrutinib, PK13 [idelalisib, 
duvelisib, copanlisib, alpelisib], 
venetoclax, OTHER [alemtuzumab, 
lenalidomide], chlorambucil, CD20 






rituximab bendamustine, ibrutinib, PK13 
[idelalisib, duvelisib, copanlisib, 





ibrutinib  bendamustine, fludrabine, 
cyclophosphamide, pentostatin, PK13 
[idelalisib, duvelisib, copanlisib, 






























ibrutinib, PK13 [idelalisib, duvelisib, 









ibrutinib, PK13 [idelalisib, duvelisib, 
copanlisib, alpelisib], venetoclax, 
OTHER [alemtuzumab, lenalidomide], 







chlorambucil bendamustine, fludrabine, 
cyclophosphamide, pentostatin, 
ibrutinib, PK13 [idelalisib, duvelisib, 
copanlisib, alpelisib], venetoclax, 
OTHER [alemtuzumab, lenalidomide] 






ibrutinib, PK13 [idelalisib, duvelisib, 
copanlisib, alpelisib], venetoclax, 
OTHER [alemtuzumab, lenalidomide], 







ibrutinib, PK13 [idelalisib, duvelisib, 
copanlisib, alpelisib], venetoclax, 





Table 3.3. Eligibility Criteria for the Nine Select Therapies and Lines of Therapy. 
 
Description and measurement of study variables 
The study assessed several independent variables which were used in our 
analyses. They include the following:  
 
Baseline patient demographics 
All demographic characteristics were documented at baseline including variables 
captured within 12 months prior to the index date.  
 Date of death 
o Age at index date (#) Calculated as: integer [ (index date – date of birth + 
1) / 365.25] 
o Age groups (<66, 65-75, 75+) 
Definitions: 
Combination=all combination and exclude criteria must be met within 60 days of the root 
drug to call the regimen a combination.  
Start date=first date for any of the root drugs, but all combination and exclude criteria must 
be met within 60 days of that date to ensure the person is on the combination therapy.  
Stop date=last date for any of the root drugs, but all combination and exclude criteria must 
be met within 60 days of that date to ensure the person is still on combination therapy.  
6MGap=if the patient does not receive the same treatment for more than 6 months, then use 
the stop date that occurred before those 6 months and call anything thereafter a new line of 
therapy (LOT). 
Lines of Therapy:  
1L= first treatment the patient received.  
2L = second treatment the patient received. 
3LP = (3L+) = third or greater treatment the patient received. 
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 Patient sex (y/n) 
o Male, female 
 Patient race (y/n) 
o White, Black/African American, Other. 
 VHA priority group (#) 1, 2-6, 7-8 
 Geographic region (VSN 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 16, 17, 19, 20, 21, 22, 
23) 
 Prior history of Agent Orange exposure (y/n) 
 
 
VA PRIORITY GROUPS 
VA priority group is a grading system that assigns a number (1 to 8) to veterans 
enrolled in the VA healthcare program, for the purpose of accessing healthcare. The 
assignation of group is primary based on military service history, disability rating, 
income level, medicaid eligibility, and other benefits received from, such as VA pension 
benefits). Highest priority is assigned to those with service-driven disability and the 
lowest is assigned to those with higher income and do not have service-connected 
disability. They utilize this priority grouping to balance healthcare demand with VA 
healthcare resources.168 Since this is a resource sharing structure, it may influence types 
of medications accessed as well as affordability by the different groups. Some features of 





1 Veterans with service-connected, rated as 
50% or more disabling, or renders one 
unemployable, or received the Medal of 
Honor (MOH) 
 N pay copays for any types of 
care, tests, or medications. 
2 Veterans with service-connected, rated as 
30% - 40% disabling 
Pays a co-pay of $8 -$9 for 
medications. 
Pays co-pay for outpatient 
services unrelated to military 
service 
No co-pay for first 3 urgent care 
visits and $30 subsequently. 
3 Veterans who are former prisoners of war 
(POW), or Received the Purple Heart 
medal, or discharged due to disability that 
was caused by—or got worse because of—
active-duty service, or have a service-
connected disability rated as 10% or 20% 
disabling, or fall into the special eligibility 
class due to being disabled by treatment or 
vocational rehabilitation. 
Pays a co-pay of $8 -$9 for 
medications. 
Pays co-pay for outpatient 
services unrelated to military 
service 
No co-pay for first 3 urgent care 
visits and $30 subsequently. 
4 Veterans receiving VA aid and attendance or 
housebound benefits or have received a VA 
determination of being catastrophically 
disabled. 
Pays a co-pay of $8 -$9 for 
medications. 
Pays co-pay for outpatient 
services unrelated to military 
service 
No co-pay for first 3 urgent care 
visits and $30 subsequently. 










5 Veterans that don't have a service-connected 
disability, or you have a non-compensable 
service-connected disability rated as 0% 
disabling and have an annual income level 
that's below VA’s adjusted income limits 
(based residential zip code). Those receiving 
VA pension benefits or are eligible for 
Medicaid programs, are assigned to this 
group. 
 
Pays a co-pay of $8 -$9 for 
medications. 
Pays co-pay for outpatient services 
unrelated to military service 
Pays co-pay for outpatient services 
unrelated to military service 
No co-pay for first 3 urgent care visits 
and $30 subsequently. 
6 Veterans who served in Vietnam between 
1962 – 1975, those discharged less than 5 
years ago, exposed to ionizing radiation 
during the occupation of Hiroshima and 
Nagasaki, served in the Persian Gulf war 
between 1990-1998, served in camp Lejeune 
for at least 30 days between 1953 – 1987 or 
served in a theater of combat operations 
after November 11, 1998 are assigned to this 
group 
Pays a co-pay of $8 -$9 for 
medications. 
Pays co-pay for outpatient services 
unrelated to military service 
$0 or $30 co-pay for first 3 urgent care 
visits (depending on if condition is 
covered by special authority like agent 
orange) and $30 subsequently. 
7 Veterans whose gross household income is 
below the geographically adjusted income 
limits (GMT) for where you live, and who 
agree to pay copay. 
Pays a co-pay of $8 -$9 for 
medications. 
Pays co-pay for outpatient services 
Pays full co-pay or reduced co-pay for 
in-patient care, if residing in high cost 
area. 
$30 co-pay for urgent care visits. 
8 Veterans whose gross household income is 
above VA income limits and geographically 
adjusted income limits for where you 
live, and who agree to pay copays. 
Pays a co-pay of $8 -$9 for 
medications. 
Pays co-pay for outpatient services 
Pays full co-pay or reduced co-pay for 
in-patient care, if residing in high cost 
area. 
$30 co-pay for urgent care visits. 
Table 3.4(CONTD) Select characteristics of VA Priority Groups (Adapted from 
https://www.va.gov/health-care/eligibility/priority-groups/ 
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VA Geographic Region  
The VA is structured into regional areas called Veterans Integrated Service 
Networks (VSN #), with numbers assigned to each regional area. Each geographical 
region oversees the operations of a number of health centers, nursing homes, outpatient 
clinics, VA hospitals, and other VA healthcare facilities. Geographic variations in 
healthcare utilization, resource allocation and access to care has been reported for the VA 
VISNs. The number of patients, average annual cost per person and resource utilization 
were shown to significantly vary across VISNs.169 
 
Specific treatment characteristics 
Specific treatment characteristics are as follows: 
 Start date is the first treatment administration date of the first dose of 
monotherapy. 
 End date is the last treatment administration date of the last dose of 
monotherapy. If the patient is lost to follow-up, then the last recorded VA visit 
date will be utilized. 
 
 Line of Therapy (LOT) 
Treatment uptake and trends were assessed on three lines of therapy namely, first 
line (1L), second line (2L), third line and above (3L+), based on the different 
treatments a patient received, their timing and duration. Treatment regimen was 
 63 
considered first-line, if index date falls within time between initial diagnosis and first 
drug claim. Thereafter, a new line of therapy occurs when a patient does not receive 
the same treatment for more than 6 months. The stop date for that regimen was 
considered as the last date that it occurred before those 6 months, and anything 
thereafter was regarded as new line of treatment (LOT). 
  
Concomitant medications (medications being taken at the time of treatment initiation) 
The electronic health record (HER) of the eligible patients was assessed, and the use 




 CYP3A4 inhibitors 
 CYP3A4 inducers 
 Gastric acid-suppressing drugs 
 Antiarrhythmics 
 Drugs used for pain 
 
Comorbidities 
We assessed Charlson comorbidities and other comorbidities as defined by ICD-9-
CM and ICD 10 codes. 
 64 
 Charlson comorbidities (y/n) and score (#, calculated) (using data in 24 
months prior to index date)  
o Fiscal years 1994-2015 (ICD-9-CM) were used.170 
o Fiscal years 2016-2017 (ICD-10) were used.134 
 Prior history of additional comorbidities (y/n) (using data in 24 months prior 
to index date) 
o Coronary artery disease, atrial fibrillation, arrhythmia, deep vein 
thrombosis, pulmonary embolism, prior bleed, lung diseases, intestinal 
disorders (Crohn’s disease and GI ulcers), high uric acid or gout, high 
cholesterol, hypertension, and rheumatoid arthritis. 
 
Defining Charlson Comorbidity Index (CCI) Scoring System 
 Charlson comorbidity score predicts 10-year survival for patients with 
multiple comorbid health conditions. Each comorbidity attracts a score of 1, 2, 3, or 6, 
based on the associated risk of dying due to that condition. Core morbidities and how to 









Age <50years 0 
50 – 59 years +1 
60 – 69 years +2 
70 – 79 years +3 
≥80 years +4 
 
Myocardial Infarction History of definite or 
probable MI, (EKG and/or enzyme changes). 
Yes  +1 
No 0 
 
Congestive Heart Failure (external or aproxysmal 
dyspnea and has responded to digitalis, diuretics or 




Peripheral vascular disease. 
Intermittent claudication or past bypass for chronic 
arterial insufficiency, history of gangrene or acute 
arterial insufficiency, or untreated thoracic or 




CVA or TIA (History of a cerebrovascular accident 
with 









COPD Yes +1 
No 0 
 
Connective Tissue Disease Yes +1 
No 0 




CONDITION SCORING CONDITION 
Peptic ulcer disease 
Any history of treatment for ulcer disease or 





Severe = cirrhosis and portal hypertension with 
variceal bleeding history, moderate = cirrhosis 
and portal hypertension but no variceal bleeding 
history, mild = chronic hepatitis (or cirrhosis 
without portal hypertension) 
None 0 
Mild +1 
Moderate to severe +3 
 




End organ damage +3 
Hemiplegia Yes +2 
No 0 
 
Moderate to severe CKD 
Severe = on dialysis, status post kidney 
transplant, uremia, moderate = creatinine >3 




Solid Tumor None 0 
Localized +2 
Metastatic +6 
   
Leukemia (acute or chronic) Yes +2 
No 0 
 
Lymphoma Yes +2 
No 0 
 
AIDS (not just HIV positive) Yes +6 
No 0 
Table 3.5 (CONTD): Charlson Comorbidity Index (CCI) Scoring System 
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Laboratory values 
Select lab values of interest were captured at multiple time points during the entire 
study period to allow for potential longitudinal analyses when necessary. The absolute 
value and dates for all lab values were obtained from EMR where available in addition to 
capturing categories (e.g. elevated, normal, low) in EMR as available. 
 White blood cell count 
 Platelets 
o Serum creatinine 
o Creatinine clearance was calculated using the following formula: 
 
CrCl= [[140 - age(yr)]*weight(kg)]/[72*serum Cr(mg/dL)] 
(multiply by 0.85 for women) 
 
Outcomes  
The primary outcome is overall survival (OS) rate for the different select therapies 
that are the focus of the study. Additional outcomes include length of survival (OS) from 
treatment initiation until death from any cause (without time limit), time-to-first treatment 
(TTFT), time to initial treatment discontinuation (TIDC), time-to-next treatment (TTNT), 
complications 6 months post therapy initiation including secondary malignancies, 
emergency room visits, urgent care visits, and hospital admissions. These outcome 




o Number of emergency room visits at 6 months post index date (#). 
o Number of urgent care visits at 6 months post index date. 
o Number of hospital admissions 6 months post index date (#). 
o Death in 6 months post index date (y/n) 
o Days of survival within 6 months index date (#, calculated) 
o Days of survival after CLL agent start date (#, calculated) 
o Days between CLL diagnosis and first drug treatment or pharmacy order 
fill. (#, calculated) 
o Survival analysis was conducted as overall survival (OS) from treatment 
initiation to death and from treatment initiation time to death by any cause. 
o Time to Next Treatment was computed as the time from the initiation of 
the first treatment of CLL agent until the start of a new treatment or 
addition of drug to current treatment regimen. 
o Treatment complications (health conditions that develop in 6 months after 
treatment start date). 
o Health conditions that develop in 6 months after treatment start (y/n, date). 
 Diffuse large B-cell lymphoma (ICD9 & ICD10) (200.6 & C83.3) 
 Hodgkin’s lymphoma (201 & C81) 
 allogeneic hematopoietic stem cell transplant (V42.82 & Z94.84) 
 Secondary malignancy (skin cancer, lung cancer, prostate cancer) 
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Calculation of some outcome variables: 
o Survival Analysis: Two approaches were used in measuring survival at the 
end of study period. Patients who did not die were censored on the last 
visit date available in the database or at study end date, whichever 
occurred first. 
 Approach 1: Overall Survival (OS) at 6 months post index date. 
OS was defined as the interval from the initiation of treatment until 
date of death from any cause within 6 months of treatment 
initiation. 
OS = [ 𝐷𝑒𝑎𝑡ℎ 𝑑𝑎𝑡𝑒 (within 6 months of index date) − 𝑖𝑛𝑑𝑒𝑥 𝑑𝑎𝑡𝑒 
+ 1]/30.44 
 
 Approach 2: Overall Survival (OS) from treatment initiation to 
death was defined as the interval from the initiation of CLL 
treatment until date of death from any cause (no time limit). 
OS = [ 𝐷𝑒𝑎𝑡ℎ 𝑑𝑎𝑡𝑒 (no time limit) − index 𝑑𝑎𝑡𝑒 + 1]/30.44 
 
Time to First Treatment (TTFT) 
Computed as time from initial diagnosis until treatment initiation. 
o TTFT = [First CLL treatment date - Diagnosis date + 1]/7.0246 
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Time to Next Therapy (TTNT) 
Computed as the time from the end of the first treatment until the start of new 
treatment. Patients who did not move on to next therapy or were still on therapy at the 
end of study were censored at the study end date or the last visit date available in the 
database.  
 
o TTNT = [Start of next therapy - first treatment end date + 1]/ 30.44 
 
Time to Treatment Discontinuation (TIDC) 
Computed as time from initial treatment until change/end in first treatment 
without treatment completion. 
o TIDC = [1st date of incomplete / discontinuation of first therapy - first 
CLL treatment date + 1]/ 30.44 
Statistical Analysis Plan and Results 
Statistical analyses were performed using JMP and SAS (SAS Institute, Inc., 
Cary, NC) statistical software. Patients were grouped according to which of the nine 
select therapies they received, also according to what treatment they received as first line, 
second line and third line+ as appropriate. Results are reported in aggregate. The number 
and percent of patients along with descriptive statistics (mean, standard deviation, 
median, and interquartile ranges, number of non-missing and number of missing values) 
are reported for continuous data. 
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Dichotomous variables are reported as counts and percentages. Categorical 
variables (e.g., age groups, lab value groups, etc.) – sometimes created from continuous 
variables –have the number and percent of patients reported. In case of missing 
observations, the number and percentage of missing are reported. Demographic and 
clinical characteristics are compared among the different strata by using Chi-
square/Fisher’s exact test (for dichotomous or categorical variables), and student’s t-test 
(for the continuous variables). Statistical significance is determined by P < 0.05. Time-to-
event outcomes were estimated by Kaplan-Meier. Log rank tests were used to compare 
survival times between groups of different treatments/agents/regimens.  
 
Ethical Considerations 
This research work does not contain any studies with human or animal subjects 
performed by any of the authors. 
 
Protection of Human Subjects 
The investigators will perform the observational study in accordance with the 
regulations and guidelines governing medical practice and ethics in the United States and 
in accordance with currently acceptable techniques and expertise. The final protocol of 
the observational study and its amendments were approved in writing by the Institutional 
Review Boards (IRBs) at the University of Texas Health San Antonio and South Texas 
Veterans Health Care System. 
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Subject Informed Consent 
Not applicable. This is a retrospective observational study. The study 
investigators received IRB waiver for the informal consent requirement. 
Confidentiality of Study/Subject Data 
 The research involves existing data only. No patients or providers were 
contacted. The data will be maintained in limited-access directories on VA research 
servers behind the VA firewall at all times. Personnel with access to the data are fully 
trained and monitored regarding knowledge and practice of good data security processes. 
Additionally, all data collection will be performed at the South Texas Veterans Health 
Care System (STVHCS), Audie L. Murphy VA Hospital, San Antonio, Texas, by 
researchers with VHA appointments. Only these researchers will have access to patient 
identifiers to enable them merge databases. All electronic data will be stored on a VA 
research server; therefore, a data security breach is unlikely. Data will be reported only in 





Aim 1: Describe trends for nine select CLL treatments from 2014 to 2018. 
Hypothesis A1.1: CLL treatments will be used equally in all lines of therapy. 
Strategy A1.1: Determine the proportion of patients receiving each select 
treatment in each line of therapy (i.e., treatment count for a given line divided by 
treatment count across all lines). Compare the proportions to determine if each CLL 
treatment was used equally in all lines of therapy. 
 
 

























































Interpretation A1.1: FR/FCR/PCR (53%), BR (44%), and Chlorambucil+CD20 
(42%) were used more frequently in 1L than the other lines. Ibrutinib (51%) was used 
more frequently in 2L than the other lines. Finally, CD20 monotherapy (78%), 
venetoclax (62%), PI3K inhibitors (60%), and Chlorambucil-CD20 (52%) were used 
more frequently in 3L+ than the other lines. 
 
Conclusion A1.1: Reject the hypothesis as there were clear differences in the 
proportions of CLL treatments used in the different lines of therapy.  
 
 
Hypothesis A1.2: Ibrutinib will be the most common CLL treatment for 1L, 2L, and 
3L+. 
Strategy A1.2: Determine the proportion of patients in each line that received 
each CLL treatment (i.e., count for one CLL treatment in a given line divided by count 
for all CLL treatments in a given line). Compare the proportions within a given line to 
determine which CLL treatments were used most frequently for that line. 
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Figure 4.2. Proportion of patients on each CLL treatment in each line of therapy 
(A1.2) 
 
Interpretation A1.2: For 1L, ibrutinib (26%) and BR (25%) were the most 
common CLL treatments. For 2L, ibrutinib (60%) was the most common CLL treatment. 




















































Conclusion A1.2: Accept the hypothesis for 1L and 2L, as ibrutinib was the most 
common CLL treatment in those lines but reject the hypothesis for 3L+ as ibrutinib was 
the second most common CLL treatment for that line. 
 
Hypothesis A1.3: Novel Agents (NA) will be used more often than Chemotherapy 
/Chemoimmunotherapy (CT/CIT) treatments in 1L, 2L, and 3L+. 
Strategy A1.3: Create NA treatment group by combining patients on ibrutinib, 
venetoclax, and PI3K. Create a CT/CIT group by combining patients on the rest of the 
treatments. Then, determine and compare the proportion of patients on NA and CT/CIT 
for each line of therapy. 
 
 


































Interpretation A1.3: CT/CIT was used more often than NA in 1L (73% vs. 27%) 
and 3L+ (62% vs. 38%). NA were used more often than CT/CIT in 2L (69% vs. 31%). 
Conclusion A1.3: CT/CIT treatments were more common for 1L and 3+L lines of 
therapy, while the novel agents were the predominant treatments in the 2L. Accept the 
hypothesis for 2L but reject it for 1L and 3L.   
 
Hypothesis A1.4: NA will surpass CT/CIT as the most common CLL treatment in the 
later years of the study.   
Strategy A1.4: Determine and plot the proportion of patients on NA and CT/CIT 
































































































Interpretation A1.4: For 1L, there was a gradual decline in the use of CT/CIT 
with a corresponding gradual increase in the use of NA. Eventually, in 2018, NA use was 
more common than CT/CIT use. For 2L, NA were more common than CT/CIT at the 
beginning of the study period. NA use increased and CT/CIT decreased throughout the 
study. For 3L+, there was a gradual decline in the use of CT/CIT, with a corresponding 
gradual increase in the use of NA. Eventually, in 2018, NA use was more common than 
CT/CIT use. 
Conclusion A1.4: Accept the hypothesis, as NA use surpassed CT/CIT use for all 
lines of therapy by the end of the study period.  
 
STUDY POPULATION FOR REMAINING AIMS: 
The overall study included a total of 1456 patients, 99% males and 1% females 
who met the study criteria. Of this number, 655 (45%) patients received one of nine 
select treatments of interest as first line (1L) CLL treatment, and these are the focus of 
the remaining aims. From this point forward, all analyses are limited to only those 655 
patients.  
Baseline Patient Characteristics 
Patients on this first line of therapy had a median age of 70 years (interquartile 
range 33-90 years), and were predominantly of white race (85%), black race (14%), and 
other races (1%). Most of the patients were between ages 65-74 years (47%), followed by 
patients <65 years (24%), and those > 74 years (29%). Major Charlson comorbidities 
observed at baseline were diabetes (with and without complications (43%), COPD (22%), 
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renal disease (13%), and congestive heart failure (10%). The average Charlson age score 
was 5 (range 1-10). Additional clinical conditions occurring at ten percent and above, 
observed at baseline include hypertension (24%), coronary heart disease (13%), 
arrhythmia (13%) and atrial fibrillation (11%). 9% of the population had agent orange 
exposure.   
 
 
Aim 2: Determine and compare Overall Survival (OS) at six months for nine select 
CLL treatments.  
 
Hypothesis A2.1: OS at six months will be higher with ibrutinib than other therapies.   
 
Strategy A2.1: Limit the study population to only those patients who had at least 
6 months of follow-up. Determine OS at six months for patients on each of the nine select 
treatments. Using the ibrutinib survival rate as the reference group, compare the survival 
rate for each of the other eight treatments using the chi-square statistic. Call p-values less 
than 0.05 statistically significant. 
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*P<0.05, with reference to ibrutinib. 
Figure 4.7 OS at 6 months for nine select CLL treatments (A2.1.) 
 
Interpretation A2.1: OS at six months was similar for all therapies (range 95-
100%), except for ‘Other’ (88%). There were no statistically significant differences 
except for ibrutinib versus Other (p=0.04). 
 
Conclusion A2.1: Reject the hypothesis, as all CLL treatments, except for Other, 



























Hypothesis A2.2: OS at six months will be higher with NA than CT/CIT treatments.   
Strategy A2.2: Limit the study population to only those patients who had at least 
6 months of follow-up. Determine and compare OS at six months for patients on NA and 





Figure 4.8 OS at six months for NA and CT/CIT treatments (A2.2.) 
 
Interpretation A2.2: OS at six months was similarly high for patients on NA 
(97.9%) and CT/CIT (97.1%) treatments, p=0.052. 
Conclusion A2.2: Reject the hypothesis as OS at six months was statistically 































Aim 3: Determine and compare OS, as a timed outcome, for patients on NA and 
CT/CIT. 
 
Hypothesis A3.1: OS will be higher with NA than CT/CIT treatments.   
 
Strategy A3.1: Construct survival curves for patients on NA and CT/CIT using 
the Kaplan Meier Method. Compare the curves using the Log Rank test. Call p-values 




Figure 4.9 Survival Analysis curves for NA and CT/CIT from treatment initiation 





Interpretation A3.1: Survival times were higher for patients on CT/CIT 
treatments than for those on NA and the difference was statistically significant 
(p<0.0001). 
Conclusion A3.1: Reject the hypothesis, as survival times were higher for 
patients on CT/CIT as compared to patients on NA. 
 
Aim 4: Determine time from diagnosis to treatment initiation (TTFT), time from 
initiation to discontinuation (TIDC), and time to next treatment (TTNT), for the 
nine select therapies. 
 
Hypothesis A4.1: Time to first treatment (TTFT), time from initial treatment to 
discontinuation (TIDC), and time-to-next treatment (TTNT), will be similar for all 
select nine therapies. 
 
Strategy A4.1: Calculate the mean ± standard deviation for each timed outcome 
for the nine select therapies. Compare and determine if there are any differences using 
















































































































IBRU 1580 ± 
1515 
(n=160) 
REF 426 ± 
434 
(n=168) 
















VEN 2399 ± 
544 
(n=2) 
0.291 128 ± 
177 
(n=2) 




CHLOR 1289 ± 
1249 
(n=115) 

























































Table 4.1. Comparative Analysis of Treatment outcomes (TTFT, TIDC and TTNT) for 







 Of all nine 1L therapies, venetoclax had the longest TTFT followed by ibrutinib 
and the PI3K therapy, but these were not statistically significant when compared 
with ibrutinib. 
 TTFT for all chemoimmunotherapies were significantly different from that of 
ibrutinib except for chlorambucil. 
 Among the chemoimmunotherapies, chlorambucil had the longest TTFT followed 
by BR, CD+Chlor and FC/FCR/PCR therapies in descending order.  
 Ibrutinib had the longest TIDC of all nine therapies, followed by CD 
monotherapy (p<0.00001), PI3K, and venetoclax. 
 The chemoimmunotherapies tended to have shorter TIDC that were significantly 
different (p<0.00001) from that of ibrutinib except for the CD 20 monotherapy. 
 TTNT was longest for FC/FCR/PCR and BR chemoimmunotherapies, followed 
by chlorambucil, CD 20+Chlor, venetoclax and PI3K. 
 Ibrutinib had the shortest TTNT next to CD 20 monotherapy. Only the values for 
FC/FCR/PCR, BR and chlorambucil were significantly different statistically from 
that of ibrutinib.  
Conclusion A4.1: BR and FR /FCR/PCR have the longest TTNT indicating 
longer remission before next therapy. They also have the shortest TIDC. Reject the 
hypothesis because all three timed outcomes were different for all therapies. 
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Hypothesis A4.2: Time to first treatment (TTFT), time from initial treatment to 
discontinuation (TIDC), and time-to-next treatment (TTNT), will be longer for novel 
agents than with CT/CIT. 
 
Strategy A4.2: Calculate the mean ± standard deviation for each timed outcome 
for the CT/CIT and NA treatments, respectively and determine if there are any 
differences between the two treatment groups using Student’s t-test. 
 
 






















Therapies TTFT ± Stdev TIDC ± Stdev TTNT ± Stdev 
CT/CIT  1015 ± 1138 
(n=473) 
137 ± 219 
(n=481) 
330 ± 358 
(n=481) 
Novel Agents 1586 ± 1500 
(n=166) 
417 ± 429 
(n=174) 













Table 4.2. Comparative Analysis of Treatment outcomes (TTFT, TIDC and TTNT) for 
CT/CIT and NA Therapies. (A4.2) 
 
Interpretation A4.2: The CT/CIT treatments had shorter TTFT than the NA 
treatments, and this was statistically significant (p<0.0001). The NA treatments had 
significantly longer TIDC and shorter TTNT than the CT/CIT treatments. 
Conclusion A4.2: Accept hypothesis for TTFT and TIDC, and reject it for TTNT. 
 
Aim 5: Determine and compare health care facility utilization (emergency room 
visits, urgent care visits, hospital admissions) at 6 months post therapy initiation 
and end of study periods, for CT/CIT and NA. 
 
Hypothesis A5.1: A higher proportion of patients on CT/CIT than those on NA 
therapies will have emergency room visits, urgent care visits, and hospital admissions 
at six months post therapy initiation. 
 
Strategy A5.1: Determine and compare the proportions of patients who utilized 
each facility-based care within six months of therapy initiation for the two treatment 





Figure 4.12 Hospital admissions, Emergency room visits, and Urgent Care visits 
for CT/CIT and NA Therapies at 6 months post index date. (A5.1.) 
 
Hypothesis A5.2: At the end of study period, a higher proportion of patients on CT/CIT 
than those on NA therapies will have emergency room visits, urgent care visits, and 
hospital admissions. 
 
Strategy A5.2: Determine and compare the proportions of patients who utilized 










































Therapy Treatment outcome 
 Hosp Admsn ER visits UC visits 
CT/CIT 328/481 (68%) 353/481(73%)  50/481 (10%) 
NA 106/174 (61%) 111/174 (64%) 19/174 (11%) 
P-value 0.0821 0.0170 0.8469 
 
Table 4.3 Comparative Analysis of utilization of health facility-based care 
(hospital admissions emergency room visits, urgent care visits,) for CT/CIT and 
NA Therapies at end of study period. (A5.2.) 
 
Interpretation A5.1 and A5.2: At the 6 months mark, there was no significant 
difference in healthcare utilization between the two treatment groups. At the end of the 
study period however, hospital admissions and ER visits were higher with the CT/CIT 
when compared with the novel agents; however, only the ER visits was significantly 
different. UC visits were similar.  
Conclusion A5.1and A5.2: CT/CIT is associated with higher ER visits and a 
tendency towards higher hospital admissions than the novel agents. 
 
Aim. 6: Determine and compare the pattern of select complications after 6 months 
of treatment in patients initiated on each of the nine select therapies. 
 
Hypothesis A6.1: There will be no difference in the pattern of select complications 
between the nine CLL therapies. 
 
Strategy A6.1: Limit the population to those who had any of the select seven 
complications at 6 months of treatment. The proportions of patients who had each of the 
seven select complications were determined for each 1L therapy. Chi square was used to 
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check for statistically significant differences in the most prevalent complication among 
the therapies using ibrutinib as reference 
 



































































































DLBCL H. Lymph Stem Cell Transp Skin Cancer Lung cancer Bladder cancer Prostate cancer
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Interpretation A6.1  
 The percentage of select clinical conditions seen after six months of therapy 
initiation are diffuse large B-cell lymphoma (19%), hodgkin’s lymphoma 
(3%), stem cell transplant (2%), skin cancer (3%), lung cancer (3%), bladder 
cancer (2%) and prostate cancer (9%).  
 Within each of the nine select therapies, diffuse large B-cell lymphoma 
(DLBCL) was the most frequent complication, followed by prostate cancer. 
 DLBCL significantly higher compared to that in ibrutinib was seen in the 
PI3K (75%, p=0.02), the group “OTHER” (44%, p=0.0002), FR/FCR/PCR 
(36%, p=0.00005), and CD20 monotherapy (29%, p=0.033). 
 In venetoclax and chlorambucil patients, prostate cancer was more prevalent 
than DLBCL. Prostate cancer occurrence was significantly more in therapies 
“OTHER” (20%, p=0.022), CHLOR (14%, p=0.011) and CD20+CHLOR 
(14%, p=0.011), with reference to ibrutinib. 
 Stem cell transplant was seen most in the “OTHER” therapy and vaguely 
present in the rest of the therapies. 
Conclusion A6.1: Diffuse large B-cell lymphoma (DLBCL), was the most 
prevalent complication for most therapies, occurring as 75% of all complications in 
FR/FCR/PCR and PI3K each, 58% (CD 20 + Chlorambucil), 46% (BR), 48% (OTHER), 
47% (Ibrutinib), 45% (CD20 Monotherapy), 31% in Chlorambucil, and 0% (venetoclax). 
Prostate Cancer was the most prevalent in other therapies. The occurrence of 
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complications was different in the different therapies, so hypothesis of no difference is 
rejected. 
 
Hypothesis A6.2: All the complications will be more prevalent in the CT/CIT therapies 
compared to the NA. 
 
Strategy A6.2: The proportions of patients who had complications were 
combined for ibrutinib, venetoclax and PI3K for each of the seven select complications to 
obtain the values for NA therapies. The proportions for all the other therapies were 
combined to create the CT/CIT group. Chi square was used to check for statistically 
significant differences between the two groups. 
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Figure 4.14 Distribution of Select Complications in CT/CIT and NA Therapies. (A6.2.) 
Interpretation A6.2: 
 DLBCL was more prevalent in the CT/CIT category, when compared with the 
novel agents’ group but this difference was not found to be statistically significant 
(p = 0.1171). 
 Hodgkins lymphoma tended to be negligible in the NA category while it was 
prominent with the CT/CIT regimens, although the difference was not statistically 


















































DLBCL H. Lymph Stem Cell Transp Skin Cancer
Lung cancer Bladder cancer Prostate cancer
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Conclusion A6.2: The two most frequent complications (DLBCL, prostate 
cancer) were more prevalent in the CT/CIT treatments than the NA treatments. The select 
complications were either similar in both the CT/CIT and NA treatmentss or tended to be 
more prevalent in the traditional chemoimmunotherapies (CT/CIT) than the novel agents. 
Null hypothesis of no difference is rejected. 
 
Hypothesis A6.3: There will be no difference in the proportion of patients with DLBCL 
complication between those on FC/FCR/PCR and ibrutinib. 
 
Strategy A6.3: The proportions of patients who had DLBCL were determined for 









Figure 4.15 Proportion of patients on FC/FCR/PCR and Ibrutinib with DLBCL (A6.3.) 
 
Interpretation A6.3: Relative to ibrutinib (14%), FC/FCR/PCR had more than 
twice the percentage of cases of DLBCL (35%, p= 0.0005). 
 
Conclusion A6.3: Patients on ibrutinib experienced less of DLBCL when 


































Aim 7: Describe and compare the uptake of 1L CT/CIT and NA therapies for black 
and white patients. 
 
Hypothesis 7A.1: The black patients will lag behind in the uptake of novel therapies 
versus the white patients. 
 
Strategy A7.1: Determine the uptake of all nine therapies in the 1L for years 
2014 -2017, for black and white patient populations. Compare the proportions using chi 
square test. 
 
 2014 2015 2016 2017 All Years 
 P-
value 
 W B W B W B W B W B  
 n=181 n=30 n=158 n=26 n=102 n=18 n=75 n=14 516 88  
BR 31% 33% 28% 38% 22% 22% 19% 7% 137(27%) 25(28%) 0.7160 
FR/FCR/PCR 16% 27% 11% 19% 11% 6% 11% 29% 66(13%) 18(20%) 0.0548 
CHLOR 16% 23% 20% 15% 20% 11% 19% 21% 95(18%) 16(18%) 0.9591 
CD20+CHLOR 7% 3% 10% 12% 11% 6% 5% 0% 43(8%) 5(6%) 0.3953 
CD20 MONO 7% 33% 4% 0% 3% 6% 4% 14% 25(5%) 4(5%) 0.9033 
OTHER 3% 0% 3% 4% 3% 28% 4% 0% 16(3%) 6(7%) 0.0853 
IBRU 20% 3% 22% 12% 30% 22% 37% 29% 129(25%) 12(14%) 0.0198 
P13K 0% 0% 2% 0% 1% 0% 0% 0% 4(0.7%) 0(0%)  
VEN 0% 0% 0% 0% 0% 0% 1% 0% 1(0.2%) 0(0%)  
CT/CIT-
OTHER 
80% 97% 77% 88% 69% 78% 61% 71% 382(74%) 76(86%) 0.0125 
Novel 
Therapies 
20% 3% 23% 12% 31% 22% 39% 29% 134(26%) 12(14%) 0.0125 
 
Table 4.4 Uptake of the 1L therapies by White and Black Patients (2014 – 2017). (A7.1.) 
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 For all therapies, chi square test showed no significant difference in use between 
white and black patients for the years 2014 – 2017 (see table A7.1), except for 
ibrutinib. 
  Ibrutinib was received more by white than black patients (p = 0.0198). 
 FC/FCR/PCR showed a tendency towards predominance use in black patients 








































 For NA group, in 2014, 20% of white patients and 3% of black patients received 
novel agents (difference of 17%, p=0.03). This gap persisted for all study years: 
2015 (23% vs. 12%, gap of 11%, p=0.17), 2016 (31% vs. 22%, gap of 9%, 
p=0.43), and 2017 (39% vs. 29%, gap of 10%, p=0.47), though not statistically 
significant (likely due to limited sample size). 
 More black patients than whites received CT/CIT each year between 2014 – 2017. 
The difference in uptake of CT/CIT between the black and white patients were 
17% (2014), 11% (2015), 11% (2016) and 10% (2017) respectively. 
 Comparing the combined four-year (2014 – 2017) use, the traditional 
chemotherapy/chemoimmunotherapy (CT/CIT) tended to be more common 
among the black patients than the whites (p = 0.0125), while the novel agents use 
was more likely in whites (p = 0.0125). 
Conclusion A7.1 The use of CT/CIT and NA for black and white patients, a 
significant relationship with race was observed. On yearly basis, the black patients lagged 
behind the whites in uptake of the novel agents. Accept the hypothesis that black patients 
will lag behind in uptake of novel agents. 
 
Aim 8: Determine if CT/CIT and NA use is different for the age groups <65 years, 
65-74 years and >74 years. 
 
Hypothesis 8: CT/CIT and NA use will be similar for all age groups. 
 
 102 
Strategy A8.1: Create three age-based groups (<65 years, 65-74 years and >74 
years) for each of NA and CT/CIT treatments. Determine the proportion of patients on 






Figure 4.19 Use of CT/CIT and NA use in different Age-groups. (A8.1.) 
 
Interpretation A8.1: 
 In the younger age group (<65 years), the CT/CIT was more predominantly used 







































 The novel agents had a higher uptake in the oldest population (>74 years) 
compared to CT/CIT. 
 In the age-group in between both classes of therapies were similar in uptake.  
 
Conclusion A8.1: The 6% difference between both classes of therapies in the 
youngest (p = 0.071) and oldest age groups (0.145), though not statistically significant, 
may be important clinically. Accept the hypothesis that use of CT/CIT and NA treatments 
are similar in all age groups. 
 
 
Aim 9: Determine if FC/FCR/PCR and ibrutinib use and uptake is different for age 
groups (<65 years, 65-74 years and >74 years). 
 
Hypothesis 9A.1: FCR and ibrutinib use will not be different within each age group. 
 
Strategy A9.1: Determine the proportion of patients on FC/FCR/PCR and 
ibrutinib respectively, within the three age groups (<65 years, 65-74 years and >74 
years). Compare differences using chi square test. 
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Figure 4.20 Use of FC/FCR/PCR and Ibrutinib in age groups (<65 years, 65-74 












































































































































 FC/FCR/PCR uptake was higher in the youngest age-group (<65 years) when 
compared with ibrutinib, with a usage ratio greater than 2:1, and the gap was 
maintained throughout the years studied; 2014 (24%), 2015 (35%), 2016 (18%), 
and 2017 (57%). 
 In age-group of 65-74 years old patients, the use of FC/FCR/PCR and ibrutinib 
did not show a distinct pattern though the uptake of ibrutinib tended to be higher 
over the years studied. 
 In the oldest age-group (>74 years), the difference in uptake between the two 
therapies is approximately a 100% in favor of the novel agents (p = 0.0011), with 
an overall upward trend. 
 
Conclusion A9.1: The uptake of FC/FCR/PCR maintained a significant lead over 
the novel agent ibrutinib, for the years studied, rejecting the null hypothesis. The 
introduction of ibrutinib did not negatively impact the use of purine analogue -based 
regimen FC/FCR/PCR in the younger patients. 
In the group of 65-74 years old patients, age did not seem to influence which of 
the two therapies was used. Null hypothesis is accepted. 
For the oldest patients’ group, ibrutinib was used more than FC/FCR/PCR, rejecting the 
null hypothesis.  
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Aim10: Compare use of FCR and ibrutinib for black and white patients in the 
different age groups.  
 
Hypothesis A10.1: There will be no difference in the use of FCR and ibrutinib for 
black and white patients in the different age groups. 
 
Strategy A10.1: Determine the proportion of white and black patients initiated on 
FC/FCR/PCR and ibrutinib respectively for each age group. Compare differences in the 
use of both therapies between the races in each age group. 
 
 % Uptake of therapy (A) % representation in sub-cohort (B) 
FC/FCR/PCR white Black p-value White Black p-value 



























Ibrutinib       



























Table 4.5 Uptake of FR/FCR/PCR vs IBRU by age groups and race. (A10.1.) 
 
Interpretation A10.1: 
In the youngest age group (<65 years); 
 21% of white patients received FC/FCR/PCR and 21% received ibrutinib 
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 35% of black patients aged <65 years received FC/FCR/PCR and 18% received 
ibrutinib. 
 A difference of 14% exits between the black and white patients in the uptake of 
FC/FCR/PCR in favour of blacks, while the difference in uptake of ibrutinib is 
3% in favour of whites. 
 Therefore, black patients in the youngest age group were more likely to receive 
fludarabine-based therapies than their white counterparts, while white patients 
were more likely to receive ibrutinib than their black counterparts. 
In the second age-group (65-74 years); 
 12% of white patients age (65 – 74 years) received FC/FCR/PCR, while 28% 
received ibrutinib. 
 8% of black patients age (65 – 74 years) received FC/FCR/PCR, while 8% 
received ibrutinib. 
 Disparity is more prominent in this age group because the gap between white and 
black patients in the use of ibrutinib is 20% in favour of whites. 
In the third age group (>74 years); 
 7% of white patients age (>74 years) received FC/FCR/PCR, while 7% received 
ibrutinib. 




Table 10.1 shows two analyses (A and B), based on race for each sub-cohort of 
white and black patients. For each race, percentage use for each age-group (A) was also 
analyzed for its equivalent proportion in the whole cohort (B) for FC/FCR/PCR and 
ibrutinib. In all age groups, a statistically significant difference in uptake was observed 
between the white and black patients, however, when analysis was based on the 
proportional representation of each race in the whole cohort, most failed to be significant 
differences. For example, for FC/FCR/PCR, 64% of whites and 36% of Blacks were 
initiated on this therapy for the youngest age-group, a difference of 28% (p= 0.013). 
Analyzing this uptake on the basis of proportional representation of whites and 
blacks in that age group in the cohort yielded 21% for whites and 35% for blacks and the 
difference was no longer statistically significant (p= 0.085) but there was a tendency for 
more black patients to receive the chemoimmunotherapy than white patients. There was 
no statistically significant difference in the proportional use of FC/FCR/PCR between the 
black and white patients in all age groups while for ibrutinib, the difference is significant 
for age-groups 2 and 3. 
Conclusion A10.1: There is a disparity in the uptake of FC/FCR/PCR and 
ibrutinib between the black and white patients across all age groups. Black patients 
younger than75 years were less likely to receive ibrutinib. Accept hypothesis of no 
difference in use of FC/FCR/PCR and ibrutinib between blacks and whites in age group 
<65 years, reject it for age groups 65-74 and > 74 years old. 
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Aim 11: Determine if 1L treatment patterns are different for patients in VA priority 
groups 1, 2-6, and 7-8. 
 
Hypothesis A11.1: The use of all nine therapies will be similar for patients in all three 
VA priority groups. 
 
Strategy A11.1: Create three clusters of VA Priority Group numbers (1, 2-3, and 
7-8). For each of the nine select therapies, assign patients to one of three clusters based 
on their VA priority group. Determine the proportion of patients in each of the three 
groups for each therapy. Compare the differences in proportions between groups 1 vs 2-3 
and 1 vs 7-8 for each therapy, using chi square test. 
 
VA Priority Group Proportion of CLL patients on 1L therapy 
     Group 1 258/655=39% 
     Groups 2-6 279/655=43% 
     Groups 7-8 118/655=18% 
 




























Table: 4.7 Distribution of patients on the select nine therapies in the VA priority 
groups. (*P<0.05 with reference to priority group 1) (A11.1.2) 
 
 
Interpretation A11.1: Uptake of all therapies was similar across all VA priority 
groups, except for BR (p=0.016) and Chlorambucil (p= 0.022), that were significantly 
different in priority group 7-8, compared to priority group 1. 
Conclusion A11.1: Between the priority groups 1 and 2-3, there was little or no 
difference in the proportion of patients for each therapy. BR and Chlorambucil were more 
significantly used in the VA Priority group 1 than in groups 7-8.  
 
Hypothesis A11.2: The uptake of CT/CIT and NA therapies will be similar for patients 
in all three VA priority groups (1, 2-3, 7-8). 
 
Strategy A11.2: Create three clusters of VA Priority Group numbers (1, 2-3, and 
7-8). For each of the nine select therapies, assign patients to one of three clusters based 
 VA Priority Group (n/N%) 
Therapy 1 2-6 P-value 7-8 P-value 
BR 76/258 (29%) 70/279 (25%) 0.256 21/118 (18%) 0.016* 
FR/FCR/PCR 36/258(14%) 39/279 (14%) 0.889 12/118 (10%) 0.308 
IBRU 68/258=26% 66/279=24% 0.470 34/118=29% 0.619 
PI3K 2/258=0.08% 0/279=0%  2/118=2%  
VEN 0/258=0% 0/279=0%  2/118=2%  
CHLOR 40/258=16% 51/279=18% 0.391 30/118=25% 0.022* 
CHLOR + 
CD20 
17/258=7% 26/279=9% 0.244 7/118=6% 0.809 
CD20 Mono 9/258=3% 14/279=5% 0.382 8/118=7% 0.154 
OTHER 10/258=4% 13/279=5% 0.654 2/118=2% 0.264 
ALL 258/655=39% 279/655=43%  118/655=18%  
CT/CIT 188/258=73% 213/279=76% 0.355 80/118=68% 0.313 
NA 70/258=27% 66/279=24% 0.355 38/118=32% 0.313 
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on their VA priority group. For the NA category, patients on the novel agents (ibrutinib, 
PI3K and venetoclax) were combined in each of the three groups and their proportion 
determined. Patients on the remaining therapies were similarly combined and proportions 
determined for CT/CIT category. Compare differences for statistical significance at 
p<0.05, for groups 1vs 2-3 and 1vs 7-8 for CT/CIT and NA, using chi square test. 
 
 
































Interpretation A11.2: The uptake of the novel agents is significantly lower than 
that of CT/CIT in all VA priority groups (p<0.00001). Although not statistically 
significant, the priority group 7-8, had the highest uptake of novel agents (32%), different 
from that of group 2-6 (24%) and group 1 (27%).  Conversely, it had the lowest uptake in 
CT/CIT (68%) when compared to the other two clusters. 
 
Conclusion A11.2: There was no significant difference in uptake of either 
CT/CIT or NA in the VA priority groups, though uptake of NA tended to be higher in the 



















CT/CIT 188/258=73% 213/279=76% 0.355 80/118=68% 0.313 
NA 70/258=27% 66/279=24% 0.355 38/118=32% 0.313 
P-value <0.00001 <0.00001  <0.00001  
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Aim 12: Determine the relationship between Charlson Comorbidity Index score and 
6 months patient mortality. 
 
Hypothesis 12.1: Charlson Comorbidity Index score will be higher in patients who die 
than in those who survive. 
 
Strategy A12.1: Create two groups of patients, one group comprising those dead 
within 6 months of treatment initiation and the second group comprising those who are 
alive. Determine the mean charlson age score for the two groups of patients for each 
therapy. Compare the average scores for both groups in all therapies. 
 
 


















 In all therapies except chlorambucil, ibrutinib and venetoclax, the mean charlson 
age scores tended to be higher for patients who were dead at 6 months (5-6), than 
for those who were alive (4-5), though this difference is small. 
 For venetoclax, the average CCI score for the survivors at 6 months was higher 
than for the dead at six months. 
 The average CCI scores for patients on chlorambucil and ibrutinib were same for 
both the survivors and the dead at 6 months of treatment initiation. 
Conclusion A12.1: There does not seem to be a clear relationship between 
average charlson age score and the outcome of the patients being dead or alive at 6 
months. However, for most therapies, average charlson age score was one point higher 
for the dead than for those surviving.  Average charlson age score did not seem to be an 
important risk factor in ibrutinib therapy, contrary to the chemoimmunotherapies (BR< 
FCFCR/PCR, Chlorambucil, and CD20 mono) therapies                                                                 
 
Hypothesis 12.2: Length of survival will be longer for the patients with lower charlson 
comorbidity index scores for CT/CIT and NA therapies.  
 
Strategy A12.2: Limit the study population to only those patients who had at 
least 6 months of follow-up. From this sub-cohort, create two groups of patients, one 
group comprising patients on ibrutinib, PI3K, and venetoclax and the second group 
comprising patients on the remaining six therapies. Determine OS (in days) for patients 
on the novel agents and CT/CIT treatments groups. Classify patients in each treatment 
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group into one of three CCI categories, stratified in accordance with Charlson age score, 
CCI 1-3 (Low), CCI 4-7 (Moderate - High) and CCI ≥ 8 (Very High). Compare the 
association between CCI scores and survival times in each therapy (CT/CIT and NA) and 





Figure 4.26 Relationship between Charlson Age Score and Survival Times within 







































 For both CT/CIT and NA, survival times tended to decrease with increasing 
charlson comorbidity scores. 
 Within each therapy, no association was determined between the CCI score and 
survival time when NA patients with low CCI were compared with those with 
moderate – high CCI (p= 0.1978) and those with Very high CCI (p = 0.0978). 
Similarly, no association was determined when CT/CIT patients with low CCI 
scores were compared with those with moderate - high CCI score (0.6648) and 
those with very high CCI scores (0.1314). 
 Overall, CT/CIT patients had significantly longer survival within 6 months of 
treatment initiation, compared to the NA patients (p = 0.031), When the two 
groups were compared at the level of the different CCI categories, at the low CCI 
score category, patients on NA had longer survival times compared to those on 
CT/CIT but not statistically significant (p = 0.776), while at all other levels, the 
CT/CIT patients had significantly longer survival, at moderate - high CCI 
category (p=0.0106).  
Conclusion A12.2: No association was found between CCI scores and survival 
times in both NA and CT/CIT therapies, so the hypothesis of longer survival for lower 
CCI scores is rejected.  
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Though patients tended to have shorter survival times as the stratified charlson 
age score increased from low, moderate- high and very high score categories, 
none of the differences was significant. 
Between NA and CT/CIT therapies, the latter had significantly longer survival 
with higher comorbidity index score than the NA therapies.  
 
Aim 13: Determine the relationship between co-medications and patient mortality at 
6 months post treatment initiation. 
 
Hypothesis A13.1: The proportion of patients on select co-medications that are dead at 
6 months will be same for all nine therapies. 
 
Strategy A13.1: Create a sub-cohort of patients who were on co-medications. 
From this sub-cohort, create two groups of patients based on 6-month mortality (Dead, 
Alive). From the group of those that were dead, determine and compare the proportion of 




Figure 4.27 Proportion of Patients on different co-medications that were dead at 6 
months, for the Nine select therapies. (A13.1.) (Note: No deaths at 6 months 





Death @ 6 months BR FR/FCR/PCR IBRU PI3K VEN 
 Dead Alive Dead Alive Dead Alive Dead Alive Dead Alive 














- 4 - 2 










- 0 - 0 
Range of # co-meds 3-6 1-8 3-7 1-8 2-6 1-8 - 1-7 - 1 
 




CD20 MONO OTHER 
 Dead Alive Dead Alive Dead Alive Dead Alive 






























Range of # 
co-meds 
6 1-8 - 1-7 - 1-8 
5-8 1-8 
Table: 4.9 Proportions of Patients  dead or alive on the nine select therapies + 























































 From our study, there was no difference in the average number of co-medications 
for those who died and those who survived. 
 Across all therapies, a greater percentage of patients were on concomitant 
medications (88%-100%) when compared with those not on co-medications (0-
16%) for both the dead and those who survived. There were no patients on 
concomitant medications that were dead at 6 months for PI3K, venetoclax, CD20 
monotherapy, and chlorambucil + CD20 therapies. 
 For patients on ibrutinib who died within six months and who were on 
concomitant medications, the most prevalent concomitant medication was acid 
reflux medications (63%), followed by antihypertensives (50%), anticoagulants 
(50%), CYP3A4 inducers (40%), and CYP3A4 inhibitors (38%). 
 For FC/FCR/PCR, the order was acid reflux medications, anticoagulants, and 
CYP3A4 inducers, each at 100%, followed by all others at 50%, except for 
antihypertensives at 20%. 
Conclusion A13.1: Proportion of patients concomitantly on various co-
medications who died within six months of therapy initiation was different for the 
different therapies. The null hypothesis of no difference is rejected. 
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Hypothesis A13.2: The proportion of patients on select co-medications that are dead or 
alive at 6 months will be same for CT/CIT and NA therapies. 
 
 
Strategy A13.2: Create a sub-cohort of patients who were on the select co-
medications. From this sub-cohort, create two groups of patients based on 6-month 
mortality (Dead, Alive). Determine and compare the proportion of patients on each co-








































































CT/CIT (Alive)   
On co-meds 7/8(88%) 144/166(87%) 9/9(100%) 428/472(91%) 
Not on co-meds 1/8(13%) 22/166(13%) 0/9 44/472(9%) 
Range of # co-meds 2-6 1-8 3-8 1-8 
 
Table 4.10 Proportions of Patients  dead or alive on CT/CIT and NA therapies + 
concomitant medications (A13.2.1.) 
 
Interpretation: 
 The data shows that patients on CT/CIT therapy who were on concomitant 
medications and dead at 6 months (100%) were greater in proportion, when 
compared to those on NA (88%), though chi square analysis does not show this 
difference to be statistically significant (p=0.471). 
 91 % of the survivors at 6 months were on co medications in the CT/CIT therapy 
and 87% in the NA therapy. That means, for patients on CT/CIT and co-
medications, there is a 9% difference between the dead and alive, similar 
difference was observed for the patients not on co-medications. This difference 
reduces to 1% and 0% for the NA therapies.  
Conclusion A13.2: Alive or dead, a greater proportion of patients were on co-
medications in the CT/CIT than NA therapies, rejecting the null hypothesis of no 
difference. Concomitant medications had a greater negative impact on mortality for 
CT/CIT when compared with the NA therapies. 
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Hypothesis A13.3: Being on each of the select co-medications will increase the risk of 
death for patients in the CT/CIT, NA, FC/FCR/PCR and Ibrutinib therapies. 
 
Strategy A13.3: From the cohort, create two groups (Dead, Alive) of patients 
based on 6-month mortality. For each group, determine the proportion of patients on each 
co-medication or not on co-medication, for the CT/CIT, NA, FC/FCR/PCR and Ibrutinib. 
Determine the relative risk of death for patients on co-medications for each therapy. 
 
Co-medication CT/CIT NA FC/FCR/PC
R 
IBRU 
On co-meds ∞ 1.07 ∞ 1.11 
Anticoagulants 16.83 2.48 ∞ 2.57 
Antiplatelets 6.37 0.98 5.21 0.97 
Antiarrhythmics 1.9 0.72 1.81 0.69 
CYP3A4 
inhibitors 
4.97 1.33 2.22 1.34 
CYP3A4 
inducers 
8.17 1.52 ∞ 1.51 
Acid reflux 2.86 2.1 ∞ 2.07 
Pain 2.56 0.63 0.53 0.6 
Anti-
hypertensives 
1.74 0.89 0 0.89 
 
Table. 4.11 Relative Risks of Concomitant Medications on 6-months mortality 
for nine FC/FCR/PCR, Ibrutinib, CT/CIT and NA therapies. (A13.3.1) 
Interpretation A13.3: 
 124 
 Of the 655 CLL patients on 1L therapy, 94% of those who were dead at 6 months 
subsequent to treatment initiation were on at least one concomitant medication, 
compared to 90% of those who were alive at the same period.  
 An analysis of the effect of concomitant medications showed an infinitely large 
relative risk of death in 6 months for the CT/CIT patients who are on various 
combinations of the select co-medications, contrary to no appreciable increased 
risk of death (RR 1.07) for same category of NA patients. 
 For the CT/CIT therapy, the greatest risk is with anticoagulants at nearly 17 times 
the risk of death when compared with those not on the medication. The order of 
effect size of the different concomitant medications on death outcome at 6 months 
is anticoagulants > CYP3A4 inducers > antiplatelets > CYP3A4 inhibitors > acid 
reflux medications, in that order. For the NA, the effects of the anticoagulants on 
the risk of death (2.5 times the risk), acid reflux (2 times the risk), and CYP3A4 
modulators (1.3 and 1.5 times the risk) seem to be most important. 
 With the novel agents, some medications such as pain medications, 
antiarrhythmics, and antihypertensives had a somewhat protective effect on 6-
month mortality, the risk of death for patients concomitantly on novel agents and 
these co-medications seem less likely. 
 For patients initiated on FC/FCR/PCR and on anticoagulant, CYP3A4 inhibitors 
and acid reflux co-medications, the risk of death is infinitely large when 
compared to those not on these co-medications. 
 For ibrutinib, the relative risk pattern mirrors that in the NA category.                                                   
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Conclusion A13.3: The effect of the select concomitant medications on 6-months 
mortality of CLL patients on CT/CIT and NA are variable, depending on which 
medication is involved. Generally, risk of death increased with concomitant medication 
for several medications, but not for others. Therefore, we cannot generally reject or 
accept this hypothesis. 
Relative risk of death was several times higher in CT/CIT category, compared to the 
NA category. Similar pattern was observed for FC/FCR/PCR and ibrutinib. Concomitant 
use of pain medications and antihypertensives seem to have reduced risk effect on the NA 




DISCUSSION AND CONCLUSION 
 
DISUCSSION 
Our retrospective study used data from the VHA for CLL patients with index date 
between 2014 -2018 to evaluate the use, trends in uptake, treatment patterns, and 
outcomes of select classes and categories of CLL therapies. Trends in uptake for the 
study years was accomplished in three lines of therapy, while further in-depth analysis of 
treatment patterns and outcome was conducted for the previously untreated patients on 
first-line CLL therapies only. 
 
Specific Aim 1 
Our study described the trends in the clinical use of frontline CLL therapeutic 
agents, from calendar year 2014 – 2018 among adult veterans receiving treatment for 
CLL from the Veterans Health System. Our results show that by the year 2014, 
chemoimmunotherapies remained the standard frontline therapy, however, rapid decline 
in their use with marked increases in the utilization of novel agents were already being 
observed, and a rapidly transitioning treatment pattern was emerging.  
Chemoimmunotherapy (FR/FCR/PCR (53%), BR (44%), and chlorambucil 
+CD20 (42%)) were primarily and more commonly used in previously un-treated 
patients, compared with their use in second line /relapsed/refractory patients (26%, 20%, 
and 31% respectively). The novel agents were employed more in second line 
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/relapsed/re-fractory treatments, compared to previously untreated patients. Ibrutinib’s 
use was 51% in 2L, and 16% in 1L. Similar pattern was seen with the other novel agents 
venetoclax (37% vs 1%), P13K (37% vs 3%) (Appendix I Table 1). However, the last 
two, venetoclax and PI3K as well as CD20 monoclonal antibody monotherapies were 
most commonly used as 3L+ (third line-plus of therapy) agents. 
If we examine the uptake by treatment line, we observe that 
chemoimmunorherapy was the most common treatment in previously untreated patients 
(1L) and in third-plus line of therapy, while the novel agents were most commonly used 
in second line for relapse patients. This is consistent with the reports of another real-
world study which found that between October 2015 and February 2018, 
chemoimmunotherapy was more common in previously untreated patients than in relapse 
patients (42% vs 23%), while ibrutinib was more common in relapse patients than 
treatment naïve patients (51% vs 39%). It also reported that overall, 44% of the patients 
received ibrutinib, followed by a third of all patients who received 
chemoimmunotherapies.109 In contrast, 55% of our study patients received 
chemoimmunotherapies overall, regardless of line of therapy, while 36% received 
ibrutinib. The reason for this difference between our findings and that of Mato et al could 
be the nature of the population and practice-setting. Their study was based on data from 
the ‘informCLL’ registry, which comprises patients from community-based practices 
who may have greater options and willingness to pay for the newer agent than the VA 
patients whose access to treatment choices are largely controlled by what the VA offers.  
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We also observed that overall, within the study period, anti-CD20 monotherapies 
(19%), BR (13%), and chlorambucil (11%), were the most common 
chemoimmunotherapies, regardless of line of therapy, while ibrutinib was the most 
common novel agent.  This is different from other studies that showed BR to be more 
predominantly used, followed by the anti-CD20 monotherapies. Investigators evaluating 
treatment records for 110,000 cancer patients and over 6.7 million drug administrations 
available in the IntelliDose® during the years 2010-2013 found that BR was the most 
common regimen used, followed by rituximab monotherapy as the second most common 
regimen across all lines of therapy.171 Patterns of CLL treatments have been rapidly 
transitioning for over a decade and half. Different studies in different practice 
settings/populations have reported different results in the real-world patterns of treatment 
among CLL patients in the United States. Our findings however are consistent with 
literature reports that evaluated CLL treatment trends using the SEER Patterns of Care 
dataset from 2008-2016 which showed that while CIT remained the standard frontline 
therapy, within the period studied, the use of Bendamustine / Rituximab (BR) had 
increased, taking over from fludarabine / cyclophosphamide / rituximab (FCR).172 Prior 
the advent of novel agents, anti CD20 agents were used commonly not just as 
components of chemoimmunotherapies but also as monotherapies in treatment of CLL 
especially maintenance therapies in refractory/re-lapse patients and older patients. 41, 173-
175 This may explain their predominant use in the third line of therapy in our study.  
In the first line of therapy, on the aggregate, the chemoimmunotherapies (73%) 
dominated the treatment landscape in treatment-naïve patients in a 3:1 ratio when 
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compared to the novel agents (27%). However, they had a decreasing trend in uptake, 
from 2014 to 2018, as the novel agents’ uptake was gradually on the increase. This 
demonstrates that the approval of novel targeted agents for first-line treatment clearly 
affected the first line use of chemoimmunotherapies, however, the latter still remained the 
preferred choice for first-line therapy at the time of our study (which included the pre- 
and post- approval of the first novel agent). 
Ibrutinib (with or without anti-CD20 agent) at 25%, was the most used agent in 
the 1L of therapy in our study, closely followed by BR (25%). It is interesting to note that 
despite the lack of approval for its unrestricted first line use in 2014, (except in patients 
with del 17p mutation), the use of ibrutinib in 1L grew from 17% of CLL therapies used 
in 2014, 21% in 2015, 2016 (30%), 2017 (37%) and 2018 (56%), taking over from BR as 
the most common first line therapy by 2016, following its approval for use in previously 
untreated patients earlier that year (Appendix I table 2). This is consistent with other 
published reports that observed similar changing treatment patterns that the use of 
ibrutinib increased from 10.5% in 2014 to 13.6% in 2015, while the use of BR declined 
from 36.1% in 2011 to 31.6% in 2015 in the 1L setting.176  
It could be explained that the use of ibrutinib in first line in 2014 and 2015 was 
not due to its approval for patients with del 17p mutation which came in 2016, since only 
about 5% of previously untreated patients have del(17p).177Another possible reason could 
be a manipulation of the system through the broad nature of FDA’s approval of ibrutinib 
use for patients who have received ‘at least one prior therapy’. It could be interpreted to 
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include patients who have not necessarily failed a prior therapy but tried one. Such 
people could very easily be placed on ibrutinib. Therefore, a patient could take a few 
days of a monotherapy and be switched to ibrutinib probably with a claim of a side effect. 
This is supported by the reports of another study that found that 10% of patients used 
ibrutinib in 1L prior to its 2016 approval for unrestricted first-line use. However, of this 
number, only 21% of the patients had 17p deletion.178 Regardless, when it was finally 
approved in March 2016 for unrestricted first line use following the result of the 
RESONATE-2 study, our study observed a surge in usage that made it a preferred 
therapy in 1L. By the year 2018, ibrutinib had received over 10 approvals for various 
uses in CLL and this will explain its use in over 56% of the patients at the point. 
Ibrutinib was predominantly used (58%) as a 2L therapy agent, it was also the 
most preferred (51%) of all therapies in this treatment line. Its preferential use in 2L is 
understandable because its first FDA approval for use in CLL was in the 
relapse/refractory cases. In the second line, ibrutinib dominated as the preferred therapy 
throughout the period studied. Its uptake increased steadily from about 51% of 2L CLL 
therapies in 2014, 54% in 2015 and 2016 each year, 56% in 2017, to nearly 60% in 2018. 
On the aggregate, in the second line uptake, almost 70% of patients were on novel agents, 
while 31% were on CT/CIT. When one examines the trend in uptake for the NA, there is 
an over 30% increase from 52% in 2014 to over 80% in 2018. This trajectory is 
understandable because all novel agents in our study were first approved for use in 
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relapse / refractory CLL. Similar to the trend in 1L, a continuous decrease in uptake of 
the CT/CIT (48% in 2014 – 18% in 2018) was also observed in the 2L. 
The anti-CD20 monotherapy was used predominantly (78%) as a third-plus line 
of therapy (3+L) agent and it was the preferred therapy (31%) in this treatment line. Here 
also, the proportion of patients on the CT/CIT was predominant in a 2:1 ratio when 
compared with the novel agents (62% versus the 34%), a result that was somewhat 
unexpected. This trend in uptake was fairly constant for the years 2014 – 2017. Most of 
the advantage for the chemoimmunotherapies was contributed by the anti-CD20 
monotherapies, their combinations with chlorambucil and BR. Perhaps this domination 
by the CT/CIT in this line of therapy may be explained by the increasing use of the 
monoclonal anti-CD20 monotherapies especially rituximab and ofatumumab as 
maintenance therapy after chemoimmunotherapy induction. Although not yet 
recommended for general clinical practice, their use in this sequence has been shown to 
yield better progression free survival compared to than observation alone.179,180 Also data 
from real world evaluation of treatment outcomes with ibrutinib show that anti-CD20 
monotherapy is one of the most common therapy employed after ibrutinib 
discontinuation.181 With the advent of the novel therapies into 1L use, some experts have 
expressed the opinion that the use of chemotherapy remains an option in third and higher 
lines of therapy especially in cases where patients failed first line and second line novel 
agents therapy, others have argued that chemoimmunotherapy has no place in refractory 
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CLL.182 Our study shows that in routine clinical practice for the period studied, 
chemoimmunotherapies were predominantly used in 3L+ of therapies in CLL treatment. 
Another observation that is worthy of note in the observed treatment patterns is 
the trajectory of another novel agent, venetoclax. While the first line use of venetoclax 
was negligible, there was a rapid increasing trend in its uptake in the 2L and 3+L lines of 
therapy, to the extent that it had surpassed that of ibrutinib as the most common therapy 
in the third and higher lines of therapy by 2018 (appendix 1, figures1 and 2). Venetoclax 
was approved for use in relapse CLL in 2016 and between that year and 2018, the uptake 
rose from 3% of all 2L CLL therapies in 2016, 9% in 2017 to 19% in 2018. Similar trend 
was observed in the third plus higher lines of therapy, 4% in 2016, 10% in 2017, and 27% 
in 2018. Two different though related reasons may explain this large growth in uptake. 
Venetoclax is currently FDA and EMA-approved for relapsed CLL with del17p13 while 
patients without del17p13/TP53 mutation, receive the PI3K inhibitor idelalisib.183,184 It is 
also considered a reasonable standard intervention in patients who fail ibrutinib 
therapy.100 184 Recent data has shown that therapy with idelalisib in the relapse setting is 
not very effective, thus, an off-label approach that is current practice is to use venetoclax 
in the relapse setting even if 17p del is absent.60,186 In addition to the fact that venetoclax 
has shown robust activity and good tolerability in CLL patients who have failed ibrutinib 
or idelalisib, it is also used in the few patients who are unable to use any of the two 
therapies. 
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Secondly, venetoclax, a BCL inhibitor has remarkable activity in CLL, especially 
in patients who have had substantial pretreatment.53 It demonstrated the potential to 
become a definitive treatment for those who achieve a complete response because it has 
the ability to cause deep remission by inducing minimal residual disease negativity, 
unlike the BCR inhibitors which have to be given indefinitely until unacceptable 
toxicities or disease progression emerge.187 Based on these, recently, venetoclax became 
the second targeted agent approved for first line use in CLL, in combination with a 
rituximab or obinutuzumab.86,73,188 This ability of venetoclax to deliver the combined 
beneficial effects of chemoimmunotherapies (definite course of treatment, high MRD 
negativity) with the efficacy of ibrutinib (long PFS), is a potential driver of the current 
upsurge in its uptake. The results of our study are consistent with these principles as the 
potential reason for the increasing surge in the uptake of venetoclax. especially as salvage 
therapy in 3L+ lines because the greatest surge in uptake was observed in the third-plus 
of therapy. 
Demographics and Clinical Characteristics of the Patients in the 1L therapy 
The average age of 70 years obtained for our population is slightly below the 72-
73 years reported for the US population but consistent with 69 – 71 years reported from 
the VA Health system9,189,190. 47% of our study population are 65 – 74 years old, 24% are 
under 65 years and 29% are over 74 years old. This is consistent with reports that 70% of 
CLL patients are over 65 years old,9 predominantly males (99%) of white race (85%), 
consistent with the knowledge that CLL affects predominantly males of Caucasian race.  
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Specific Aims 2 and 3  
Our study found no statistically significant difference in overall survival at six 
months for the nine select 1L therapies, using ibrutinib as the reference. OS was 
measured in terms of the percentage of patients surviving at 6 months post treatment 
initiation. The survival rate (Appendix 2, table 1) for patients on ibrutinib was 95%, BR 
(98%), FC/FCR/PCR (98%) and chlorambucil (99%). Only the group “OTHER” therapy 
was significantly lower in the proportion of survivors. On the aggregate, there was no 
significant difference in overall survival rate at 6 months between the novel agents and 
the chemoimmunotherapies. The Kaplan Meier curves show that survival probabilities 
are higher for the chemoimmunotherapies than for the novel agents (figure A3.1)  
These observations are somewhat unexpected and concerning, considering 
literature reports of the impact of the novel agents especially ibrutinib, and venetoclax on 
frontline CLL therapy. Ibrutinib was approved for first line use based on the clinical trial 
result that demonstrated improvement in median PFS and OS in patients treated with 
ibrutinib (indefinite) versus chlorambucil (48 weeks). We may not be able compare our 
study with the finding of 98% survival rate at 24 months for ibrutinib, with a relative risk 
of death that was 84% lower in the ibrutinib group than in the chlorambucil group 
(hazard ratio, 0.16; P=0.001).191 This is because of the limited time period (6 months) for 
the OS analysis in our study, which is much shorter than the 24 months for the 
RESONATE-2 study. Furthermore, there may be limitations of sample size and other 
confounders such as comorbidities, 17p del status, and disease severity (Rai staging). The 
RESONATE-2 study population was a more fit group with one third of the patients 
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having a cumulative illness rating scale score greater than 6 (suggestive of a relatively fit 
cohort) and Eastern Cooperative Oncology Group (ECOG) performance-status score of 2 
or less (on a scale from 0 to 5, with 0 indicating no symptoms and higher numbers 
indicating increasing disability). However, the mean CCI score in our study was 5, 
indicating a cohort of patients with intermediate to high severity comorbidities. Our study 
did not exclude patients based on genetic aberrations and disease staging while the 
RESONATE-2 trial excluded patients with 17p del. 
 
Specific Aim 4  
In our findings, targeted therapies, venetoclax, ibrutinib and PI3K had the longest 
time to first treatment (TTFT) among the nine select therapies. TTFT for BR, CD + Chlor 
and FC/FCR/PCR, were all significantly shorter than that of ibrutinib. Patients with early-
stage, low risk (Binet 0) are normally not treated until disease progression according to 
NCCN and iwCCL guidelines. Generally, the pattern seen on the aggregate level, is that 
patients initiated on the novel therapies had significantly longer TTFT, longer time to 
initial treatment discontinuation (TIDC), and shorter time to next treatment (TTNT) when 
compared with those initiated on chemoimmunotherapies (p = 0.00001). About 30% of 
all newly diagnosed CLL may never go into treatment, while it takes a median of 7 years 
for patients with low to intermediate risk to initiate therapy, and 2 years for high or very 
high-risk patients.32 Therefore, the nature and aggressiveness of the disease determines 
how early treatment should be initiated. It follows then that the more aggressive disease 
tends to go into therapy sooner. From our study, patients initiated on 
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chemoimmunotherapies had a shorter time to first treatment, meaning that the more 
aggressive diseases were initiated on chemoimmunotherapies (2.8 years) compared to the 
novel agents (4.3 years). The TTFT of 3.2 years observed for all patients in our study 
agrees with the 3.4 years reported in another real-world study.109 It could be attributed to 
the fact that the CT/CIT were the preferred choice in first line therapies at the time of our 
study, therefore, most previously untreated patients were inadvertently initiated on them. 
The CT/CIT are also reported to be more effective at debulking tumors and reducing 
initial tumor burden, favoring their use when early intervention or sequential use is 
required for aggressive tumors and the possibility of eliminating minimal residual 
disease.  The GCLLSG is currently testing this concept with a ‘debulking regimen’ 
consisting of chemoimmunotherapy (up to 2 cycles of bendamustine), followed by 6 
cycles of induction therapy with targeted agent (1 to a maximum of 3 of ibrutinib, 
acalabrutinib, idelalisib, or venetoclax) in combination with an anti-CD20 antibody 
(obinutuzumab or ofatumumab), followed by MRD-guided maintenance therapy.102 With 
this, results have shown that more than 90% of patients achieved MRD-negative 
remissions. The chemoimmunotherapies are also reported to be less tolerable due to 
toxicities, which could be the reason for the shorter time to treatment discontinuation. 
Our results observed that time to next treatment (TTNT) following treatment 
discontinuation for novel agents (5.5 months), is shorter when compared with 
approximately 15 months for the CT/CIT. 
The longer time to treatment discontinuation (TIDC) for the novel agents (14 
months) observed in our study compared to the CT/CIT (5 months), is consistent with 
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other published finding that almost 90% of patients on ibrutinib therapy in a study, did 
not initiate a new treatment after 2 years, indicating a longer time to treatment 
discontinuation.192 The implication of these results is that the novel agents will be used 
for those patients who have a more indolent disease and need to stay longer in the wait-
and-watch stage and have a mild or slow growing CLL, for whom aggressive treatment is 
not required. CT/CITs have definite treatment protocols which may have been captured 
as treatment discontinuation in the study, contrary to the novel agents with indefinite 
treatment regimen. before disease progression and next therapy and shorter duration to 
treatment discontinuation. 
 
Specific Aim 5 
Our study evaluated the use of health care resource utilization by the patients on 
novel agents and chemoimmunotherapies, using attendance to three facility-based care, 
hospital admissions, emergency room visits and urgent care visits. We found hospital 
admissions were slightly lower for patients on NA though not statistically different from 
that of the CT/CIT (p=0.0821), ER visits was significantly lower for the NA patients 
(p=0.0170) and no difference in urgent care visits. These findings are similar to those 
reported by another real-world study that ibrutinib therapy was associated with fewer 
days in the ER or outpatient services, fewer hospital admissions, although, these were not 
significantly different from that of CT/CIT.192 The authors suggest that the higher 
efficacy seen with ibrutinib therapy may be the driver behind the observed lower 
healthcare facility utilization. However, this opinion does not account for the different 
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toxicity profiles for ibrutinib and CT/CIT. The CT/CIT is used more for younger fit 
patients because the therapy requires good renal and hepatic function to reduce the 
potential for its toxicities, while ibrutinib is used in patients with more diverse health 
status, indicating that the CT/CIT elicit more acute and toxicities that will warrant the use 
of hospital-based care or ER visits. The reduced healthcare facility-based care for novel 
agents may become important in their use due to pharmacoeconomic issues.  
 
Specific Aim 6 
Our study evaluated the existence of seven select clinical conditions that are 
considered secondary malignancies in CLL, for the nine select therapies in our cohort. 
We observed that overall, diffuse large B-cell lymphoma (DLBCL) at 19%, was the most 
prevalent complication in the cohort. DLBCL also known as Richter’s Syndrome (RS) is 
a more aggressive B-cell lymphoma. Literature reports that between 2–8% of CLL 
patients will experience transformation of their disease into this complication.193-195 It is 
not well understood, what risk factors promote the development of DLBCL and if such 
are based on the underlying biology of the disease, the duration of the disease, and 
treatment of the disease or the role of the CLL therapy. Our study showed that of the 
frontline therapies, DLBCL was most prevalent in the patients initiated on PI3K 
inhibitors, followed by the group “OTHER” (44%) and purine analogues- based therapy 
FC/FCR/PCR (36%). It was least prevalent in patients initiated on Chlorambucil (11%), 
chlorambucil + CD20 (14%) and ibrutinib (14%). Our result does not show any pattern 
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between the prevalence of DLBCL and the different therapies. This is consistent with 
literature reports of different prevalence rates for DLBCL for the same CLL therapy from 
different studies, 1.6% from the CLL4 trial and 4.1% from the CLL8 study.81,196 It is not 
known whether the risk is primarily driven by the treatment itself or the same biological 
characteristics of CLL that determine TTFT and prognosis. It is also not known whether 
the risk of developing RS is treatment driven. In another study, RS appeared in nearly 
half of the patients before initial therapy for CLL was required. indicating that the 
underlying risk of developing DLBCL in CLL patients may be independent of treatment 
to some extent.197 Another study showed that RS occurred prior to CLL treatment and 
after treatment of CLL in 46% and 54% of newly diagnosed patients, respectively, after 
median follow-up of 4 years.198  Since we only obtained data on the prevalence of the 
select complications 6 months post therapy initiation, we are unable to make inferences 
on whether ourresults are treatment induced or not. 
In our study, of the chemoimmunotherapies, DLBCL was seen the most in 
patients on FC/FCR/PCR, where it was 75% of all the complications seen in patients on 
this therapy. We also observed that on the aggregate, more patients on CT/CIT (20%) had 
DLBCL than those on NA (15%). This difference was not statistically significant, and we 
do not have an explanation for the observation because the possible role of the intensity 
of CLL therapies in the development of RS is not fully understood.43,62, 136,196, 199-202 
Exposure to combination of purine analogue-based and alkylators CLL therapies 
positively associated with increased risk for developing RS.198 This was from the study of 
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a large cohort of newly diagnosed patients that evaluated the impact of both biological 
characteristics at diagnosis and treatment exposure on the risk of developing RS. There 
was no association found when patients were exposed to only one component of the 
combined therapies. Our study result tends to suggest that DLBCL is more in the more 
aggressive and intense treatments, because within the therapies, chlorambucil (± anti-
CD20 antibodies), Ibrutinib, had the lowest prevalence of DLBCL, while the PI3K and 
FCR/PCR had the highest. 
A comparative analysis of the prevalence of DLBCL in patients on ibrutinib 
compared to those on FC/FCR/PCR shows significantly (p= 0.0005) that fewer patients 
on ibrutinib (14%) experienced this complication vs 36% for FC/FCR/PCR. Our finding 
is consistent with studies that show ibrutinib to be a promising target drug for the 
treatment of DLBCL. In a case series of four ibrutinib-naïve patients with DLBCL, 
ibrutinib resulted in one complete response and two partial responses, within a median 
duration of six months therapy.203 Other responses varying between 15% - 90% in clinical 
trials have also been reported.204,205 
Specific Aim 7 
Comparing the aggregated (2014 – 2017) use of CT/CIT and NA for black and 
white patients, our study observed a significant relationship with race. The use of the 
traditional chemotherapy/chemoimmunotherapy (CT/CIT) tended to be more common 
among the black patients than the whites (p = 0.0125), while the novel agents use was 
more likely in whites (p = 0.0125). Also, on yearly basis, the black patients lagged behind 
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the whites in uptake of the novel agents, while the CT/CIT therapies use was higher in 
blacks than whites. This observation is somewhat concerning because the choice of CLL 
therapy for a patient is guided by factors such as age, disease staging, comorbidities, 
presence /absence and type of genetic aberration, and frailty, not race and ethnicity. 
Literature reports that although the VHA is committed to equal health care quality and 
access to all veterans, racial disparity has persisted across a wide range of clinical areas 
and services, with some veterans in ethnic/minority groups still have reduced services 
and poorer health outcome. The black veterans were the group mainly affected in the 
mortality disparity for several clinical conditions.206 Another study in the VHA showed 
that the 3-year mortality of colon cancer was higher in blacks than white veterans (3-y 
OR = 1.28 (95% CI = 1.04. 1.56)). After adjusting for age, gender, marital status charlson 
comorbidity score, history of cancer, and year of diagnosis, they found that the disparity 
was attributable to within- hospital differences.207 Such disparity has been reported to be 
most prevalent in areas involving medication adherence, quantity and quality of provider 
communication, shared decision making and patient participation and that minorities in 
VHA are receiving fewer and lower quality services despite their greater need.208 Cancer 
management is one clinical condition where such disparity has been identified in the 
VHA and one that incorporates all the potential sources of disparity listed above. The 
implication of this for clinical practice may be significant in mortality because patients 
may receive treatments that are less than optimal for their disease, with attendant poorer 
outcome. Other authors have also reported that poverty, race and age were notable drivers 
in the selection of treatments in their population of CLL patients, in their study using 
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Medicare data.209   Similar variations in patterns in practice was also reported in the 
management of non-Hodgkin lymphoma.210 It has been suggested that uncertainty in 
relative effects of new treatment, age, race and poverty-related issues create imbalances 
in the uptake and assimilation of new technology.211, 212 This could be plausible reason for 
the observed disparity.    
However, from our studies we are unable to ascertain with firm conclusions that our 
result reveals a racial / ethnic disparity because we are unable to determine the cause of 
the observed differences. The Institute of Medicine defines disparities as “racial or ethnic 
differences in the quality of health care that are not caused by access-related factors or 
clinical needs, preferences, and appropriateness of intervention.”213  
 
Specific Aim 8 
The chemoimmunotherapies such as FCR have been employed in the treatment of 
patients who were ‘fit’ enough to withstand the toxicities. Typically, this excluded the 
frail, elderly and patients with moderate to severe comorbidities. For the latter group of 
patients, chlorambucil + immunotherapy was traditionally used until the advent of the 
targeted therapies. Recently other therapies such as ibrutinib monotherapy, venetoclax + 
Obinutuzumab have shown better outcomes in the elderly, the frail and persons with 
comorbidities. Our study observed the chemoimmunotherapies were predominantly used 
in the youngest age group (26%), while the targeted therapies were used most in the 
oldest age group (33%). This finding is consistent with reports from Mato et al 2020, that 
chemoimmunotherapies were predominantly used in the patients younger than 65 years 
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(42%), while ibrutinib was used more than chemoimmunotherapies for patients older than 
65 years (55%). Our numbers however, differ from theirs. Several studies have shown 
that the chemomimmuotherapies have excessive toxicities that make them unsuitable for 
older patients who are known to also have more comorbid health conditions even though 
the former gives deeper remission. A retrospective analysis of 949 CLL patients which 
compared different CT/CIT therapies in persons older than 70 years and those younger 
than 70 years, found that only a very small portion of the older patients were able to 
tolerate the chemoimmunotherapies and receive effective treatments.214 The targeted 
therapy ibrutinib has received approval expanding its use for all CLL indications, 
irrespective of age, genetic mutations status and performance status. It has remained the 
preferred first line therapy approved for use in all patients except for patients younger 
than 65 years with mutated IGHV. It follows therefore that the novel agents will be the 
treatment of choice for most elderly persons who are frail and possess many 
comorbidities and may not be able to tolerate the chemoimmunotherapies well. Our 
finding seems to be consistent with this principle. 
 
Specific Aims 9 and 10 
Our study cohort comprised patients 18 years – 90 years, subdivided in three age 
groups of <65 years, 65 -74 years and < 74 years.  
 The clinical situation which remains largely undecided is the use of FCR versus ibrutinib 
in young patients, especially those with mutated IgHV. Studies have shown no difference 
in PFS, in the use of either therapy in these patients.215 Current version of NCCN 
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guidelines still recommend the use of FCR for fit younger patients, since it has been 
shown to give better outcome by producing longer PFS with lower MRD negativity.216 
Generally, in the United States of America, fit patients are defined as those younger than 
65 years of age with a good performance status. In Europe, an additional criteria of 
creatinine clearance greater or equal to 70ml/min or a comorbidity rating scale score of 6 
or less is required. Such patients are thought to be good candidates for FCR therapies as a 
front-line treatment because a close to 95% response rate and complete response of 40% -
75% have been associated with this therapy in this population.43,47 Following the result of 
the ECOG-E1912 study that demonstrated longer PFS ibrutinib + rituximab in treatment 
naïve CLL patients younger than 70 years, when compared with FCR, and the subsequent 
FDA approval, NCCN guidelines currently recommends the use of either therapy in 
younger fit patients, the choice of which treatment should be shared decision with regards 
to toxicity profile of the agents, IGHV status of the patient and convenience of therapy 
(whether to take chronic ibrutinib therapy or have a “one and done” approach with a 
course of FCR).90, 215 The data from our study found that FC/FCR/PCR compared to 
ibrutinib was significantly used more in the age group <65 years old (p<0.00001), and 
this predominance existed for every year studied. The reason for this observation could 
be that most patients prefer the option of a possible cure with FCR, based on its ability to 
produce low MRD negativity with the shorter (definite) course regimen compared to 
ibrutinib, which on the other hand, produces longer PFS with chronic use. Studies have 
shown that most patients prefer treatments that promise longer PFS, even if that means 
enduring significant adverse effects.113 It could also be that our study predates the 
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approval of ibrutinib use in this population, however, this is unlikely reason because the 
dominance of FC/FCR/PCR in this young population was maintained beyond the 
approval years of ibrutinib use in the population. This finding shows that FCR is still a 
frontline therapy in the youngest population, the introduction of ibrutinib did not 
negatively impact the choice of this therapy in this age-group because the uptake of FCR 
remained significant lead over ibrutinib for each year studied. 
 On the other hand, ibrutinib was significantly (p=0.0011) used more in the 
age-group of patients older than 74 years. In patients 65 – 74 years old, there was 
similarity in uptake of both therapies, although ibrutinib was slightly but not significantly 
more. 
 When we evaluated the distribution of both therapies in black and white 
patients in all age groups to determine if race was an impacting factor. The data showed 
that black patients younger 75 years, were significantly less likely to receive ibrutinib 
while predominantly receiving FC/FCR/PCR more than their white counter parts in the 
youngest age group (<65 years), regardless of the fact that whites were the predominant 
patients in each age group. 
 However, in patients older than 74 years, black patients predominantly 
received ibrutinib compared to the whites. The reason could be that the clinical 
presentation of the disease in the black patients indicated a more frailty, which influenced 
the choice of ibrutinib over FC/FCR/PCR. Literature reports that there are racial 
differences in CLL patterns of presentation and outcomes. A report on CLL/SLL study 
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using 13 SEER registries, suggests that African Americans in the United States present 
with more advanced-stage CLL disease.217  
  This is corroborated by a more recent study which showed that African 
Americans with CLL presented more with CLL clinical characteristics associated with 
worse outcomes, for example, lower median hemoglobin levels, higher beta2-
microglobulin (b2-m) levels, higher prevalence of unmutated IGHV gene (65% versus 
47%), ZAP70 expression (58% versus 32%), and chromosome 17p or 11q deletion (28% 
versus 17%).218  
 Our study is the first and only study to evaluate the use of FCR and ibrutinib 
therapies in different age-groups and different races/ethnicities in the real-world settings, 
therefore, were unable to find comparator studies for our findings. However, the finding 
that FCR was used predominantly in the younger patients when compared to older ones, 
shows a compliance with the recommendations of NCCN treatment guidelines.  
 
Specific Aim 11 
On the aggregate, the use of CT/CIT was significantly higher than NA use in each 
VA priority group. Uptake of most therapies was similar across all VA priority groups, 
using group 1 as reference, but BR and chlorambucil were significantly used more in 
group 1, compared to group7-8. While there was no notable difference in the use of all 
nine select therapies between VA group 1 vs group 2-6, certain differences existed 
between group 1 vs group 7-8. BR and chlorambucil are the top two 
chemoimmunotherapies used in the cohort. They are not as effective as the novel agent 
 147 
ibrutinib however, the latter will have a higher out of pocket cost. The use of BR and 
chlorambucil is lowest and the use of ibrutinib is highest in the VA priority group 7-8, 
compared to the other groups. This trend seems to correspond with access to VA 
healthcare benefits and the affordability of heath care in the groups. The priority group 
assignation affects how soon veterans are signed up for healthcare benefits and what they 
pay towards their cost of care. Group 1 receives free healthcare and no co-pays while 
groups 7-8 are high income veterans or those residing in high income zip codes, while 
groups 2-6 are a mixed-bag of veterans between the two. VA Groups 7-8 is made up of 
those veterans whose income though is below the geographically adjusted income for 
where they live, they agree to pay co-pays (group 7) as well as high income earners, 
living in areas whose adjusted income is above VA income limits who also agree to pay 
co-pays (group 8). These groups are expected to pay full co-pay for outpatient and in-
patient care, as different from the other groups. It is expected that cost will not be a 
limiting issue in their uptake of better/more expensive health care due to higher ability to 
pay for care. The higher or more enhanced a priority group is, the sooner the members are 
signed up for immediate care and the more VA benefits accrues towards paying for 
members cost of care. Veterans who have service-connected disabilities are assigned to 
the highest priority group in the VA, while those who do not have service-related 
disabilities that qualify them for monthly disability compensation, and earn a higher 
income are assigned to the lowest. VA priority groups 1-3 receive some healthcare 
benefits for individuals who have service-connected disabilities, discharged due to 
disabling injury acquired on active duty or have received some awards for valor. 
 148 
Assignation to the groups 1-3 is not based on income, financial -status or zip code. For 
groups 4-6, there are some income-based and financial status criteria built into their 
eligibility, while groups 7-8 are income and financial status driven. It may mean that 
priority group 7-8 members are able to pay for the more expensive and efficacious novel 
agents. In support of this may be the data that shows the population of CLL patients 
accessing care from the VA in our study, to be lowest in the priority group 7-8. This 
could mean that these veterans are able to afford other health insurance coverage and thus 
access care from other facilities outside the VA. 
 
Specific Aim 12 
Average charlson age score in our study population was 5, which would be 
considered an intermediate disease severity score. Conflicting information and data exist 
concerning the impact of comorbid health conditions in predicting the prognosis of CLL 
disease and treatment outcomes, especially in the 1L setting. Some researchers have 
presented data showing no association between measures of comorbidity (such as CIRS 
and CCI scores) and event free survival while others report significant predictive ability 
of comorbidities on OS and PFS.129,219-223 Our study found that the presence of comorbid 
conditions did not significantly affect overall survival (survival time) because CCI score 
did not have an association with survival time, either in the novel agents or the 
chemoimmunotherapies as shown in FigureA12.2 and Appendix III, table 2. This 
suggests that the presence of the charlson comorbidities was not a major determinant in 
survival but rather the CLL disease. Comorbidities are important determinants in the 
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selection of treatment protocol, due to their impact on organ function, performance status 
and “fitness”, and therefore, the ability for a given patient to tolerate aggressive 
therapy.224,32,225 However, they do not feature as major considerations in determining 
disease severity, which in turn impacts prognosis.  Our findings tend to align with these 
principles and are consistent with other published reports that cumulative presence of 
four major comorbidities (ischemic heart disease, diabetes mellitus, chronic obstructive 
pulmonary disease and second primary malignancy) in CLL patients did not have a 
statistically significant impact on overall survival in a multivariate analysis, while age (p 
= 0.0001), Rai risk (p<0.0001) and year of diagnosis (p<0.0001) were significant 
predictors of OS.147 In elderly patients ≥65 years, regardless of the significant difference 
between the median CIRS-G score of 7 for patients who had more comorbidities, versus 
those who had 4, no association with survival was found.226 Another study also observed 
no difference in overall survival based on the number of comorbidities present (p 
=0.67).129  Our observation is also consistent with the report that No association was 
found between CCI and overall CLL-related or unrelated death, however,  5-year overall 
survival decreased with increasing CCI score, but this trend had no effect on statistically 
significant effect on mortality. 232  
We also observed that overall, patients with comorbidities initiated on the 
chemoimmunotherapies had significantly higher OS when compared with their 
counterparts on targeted therapies (p = 0.031). Other studies have suggested that there is a 
relationship between high morbidity index score and poorer treatment outcome with 
ibrutinib therapy. In a multicenter cohort study of patients treated with ibrutinib, high 
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morbidity index score correlated with inferior event free survival and overall survival in 
both 1L and R/R settings.227  
 
 
Specific Aim 13 
At baseline, patients took a median of 3 medications at least six months into their 
index date. Reports of existing studies on the potential drug interactions in patients 
receiving TKIs show that acid suppressants including proton pump inhibitors, histamine 2 
receptor antagonists and antacids was the most frequently implicated pharmacologic class 
interacting with TKIs.228 Also, literature reports that a higher percentage of TKI-proton 
pump inhibitor users died when compared with those not on that combination.229 Also, 
100% of those on the FR/FCR/PCR therapy who died within the six months period 
following treatment initiation, were on acid reflux medications. In our study, the highest 
odds for death on the aggregate was seen with the anticoagulants, followed closely by the 
acid suppressants.   
Contrary to the increased risk of death with concomitant medications seen at the 
6-month period, the relative risk of a death outcome for patients on concomitant 
medications decreased when measured at the end of study, a trend that is similar in both 
the CT/CIT and the NA therapies. This may be indicative that the effect of concomitant 
medications in the all-cause death was smaller at this level because other long-term 
mortality risk factors may be in play at this time. 
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More importantly, the somewhat protective effect seen with antiarrhythmics and 
antihypertensives for the NA was lost while that of pain medications subsisted. This 
occurrence was demonstrated more clearly in the ibrutinib therapy. It seems that the 
presence of the antihypertensives and antiarrhythmic agents initially prevented the 
development of these CV adverse effects of ibrutinib in the first few months following 
ibrutinib initiation, but subsequently was overcome by the worsening of these conditions 
overtime, as precipitated by the novel agent.   It is known that potential cardiovascular 
toxicities of ibrutinib include cardiac arrythmias and atrial fibrillation.230 Real world 
studies of ibrutinib also reveal that hypertension of any grade is much higher in patients 
than the 5% reported in clinical trials. A retrospective study of 562 adult patients with 
lymphoid malignancies treated with ibrutinib showed that 78.3% of patients developed 
new or worsening hypertension.  Of the 38.2% patients without a baseline hypertension, 
71.6% developed new hypertension while on ibrutinib in 4.2 months. O the 61.7% of 
patients who had hypertension, there was worsening in 82.4%. The study also found that 
cases of new or worsening hypertension occurs early within 4 months, with a full 
manifestation of effects at over 30 months.231  
The clinical significance of this polypharmacy may be seen in the higher relative 
risk of death for those on the concomitant medications.  
 
IMPLICATIONS FOR CLINICAL PRACTICE 
The use of chemoimmunotherapies (CT/CIT) such as BR, FCR regimens were a 
standard of care in CLL management, especially in previously untreated patients. Until 
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recently, their use remained common place in real-world clinical settings, but was fast 
declining over the years studied. 
The CT/CIT were predominantly used in 1L and 3+L of therapies, the novel 
agents (targeted therapies) were predominant in the 2L. 
As at the time of our study, ibrutinib was the only single-agent targeted therapy 
approved for CLL in the front-line setting regardless of TP53 mutation. It fast took over 
from the chemoimmunotherapies as the preferred therapy in both first and 2nd lines of 
therapy. 
The purine analogue-based therapy FCR was still predominantly used in the 
youngest population of CLL patients (<65 years), while ibrutinib was preferred therapy in 
patients older that 74 years. Both therapies were equally used in the CLL patients 
between 65 and 74 years 
Disparities were observed between the African-American and Caucasian patients 
in the use of the novel agents. Black patients lagged behind in the uptake and use, 
compared to their white counterparts. 
Between FCR and ibrutinib use, black patients were more likely to receive FCR in 
the patients younger than 74 years old, while white patients were more likely to receive 
ibrutinib. It needs to be determined if this racial disparity is driven by biology and clinical 
presentation of the CLL in both races. 
Use of novel agents resulted in significantly fewer emergency room visits and 
tendency towards fewer hospital admissions, compared to the chemoimmunotherapies. 
The pharmacoeconomic impact of the novel agents may be weighed against the potential 
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cost savings from lower health care facility utilization when compared with the 
chemoimmunotherapies. 
The novel agents were significantly associated with longer TTFT and longer 
TIDC with shorter TTNT, indicating that patients on these therapies took longer to 
commence treatment and they stayed longer on treatment but relapsed faster after 
treatment discontinuation. This observation becomes important in the choice of therapy 
for patients initiating treatment from the ‘wait-and-watch’ stage. The decision of which 
approach to treatment will be between; longer time to first treatment, with chronic 
medication use and shorter time to next treatment if discontinuation happens or earlier 
start to treatment with a ‘one-and-done’ treatment course and longer time to next 
treatment. 
Diffuse large B-Cell lymphoma was the predominant complication in patients on 
all select therapies in our study, and generally, no significant difference was observed in 
its prevalence between chemoimmunotherapies and targeted therapies. However, DLBCL 
was significantly lower in patients on ibrutinib compared to those on FC/FCR/PCR. This 
observation may become important in the choice of therapy for those patients (such as 
those of IGHV mutated status) who are at risk of developing Ritcher Syndrome. 
We did not observe any clear relationship between the average CCI score and 
death outcome for both the chemoimmunotherapies and novel agents., however, length of 
survival tended to increase with decreasing comorbidity severity. This was more evident 
in the chemoimmunotherapies. Therefore, for patients where comorbidity is a serious 
consideration in the choice of therapy, novel agents may be preferred. 
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Co-medications being taken at the time of treatment initiation was important in 
death outcome at 6 months for both the CT/CIT and novel agents at aggregate and 
individual levels. The type and not number co-medications was associated with relative 
risk of death. The risk of death while on co-medications generally is higher with the 
chemoimmunotherapies, however, different medications pose different levels of risk for 
the individual therapies. Anticoagulants, acid reflux medications, CYP3A4 inducers and 
antiplatelets present a high level of risk in FC/FCR/PCR therapy, while anticoagulants, 
acid reflux medications and CYP3A4 inducers are important for ibrutinib. Certain 
medications such as antihypertensives were also shown to lower the risk of death 
especially in ibrutinib therapy. Considering the increased risk levels, it becomes 
important to conduct a   careful assessment of patients on acid reflux meds, anti platelets, 
anticoagulants and CYP modulators, in the choice of therapy for CLL management. 
 
CONCLUSIONS 
The targeted therapies especially ibrutinib has become standard of care in CLL 
treatment at the expense of the chemoimmunotherapies. However, the latter still has use 
in a sub-population of young CLL patients and in higher lines of therapy.  The treatment 
pattern observed during our study period seem to be consistent with NCCN guidelines as 
well as the rapidly changing CLL treatment landscape and practices. Some principles that 
guide current practices and treatment guidelines are supported by evidence from our 
findings, however, other findings indicate that certain practice experiences are not. For 
example, treatment decisions observed from our study that FCR is more commonly used 
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in younger patients are in compliance with guidelines, but the use of BR over FCR may 
be more of practice-informed rather than guideline driven because FCR demonstrated a 
better PFS than BR in clinical trials. 
Selection bias still exist in real-world treatment of CLL, despite the existence of 
treatment guidelines. Driving factors could be physicians clinical judgement of who will 
benefit more from certain treatment, readiness and willingness to adopt new technologies 
and treatment innovations. 
The effect of pharmacotherapy - related issues such as drug-drug interactions from 
concomitant use of medications on outcomes of CLL treatment, appear to be more 
important in CLL-management than currently known. More research in this area is 
warranted. 
 
STRENGTHS AND LIMITATIONS 
Strengths 
Our findings are based on real-world clinical data obtained from a patient 
population that would likely be encountered during routine clinical practice contrary to 
the selected, streamlined and more strictly controlled clinical trials patients. Our 
observations therefore will reflect true events and outcomes associated with CLL disease 
and its management. 
Our study is unique in that it looked at a wide range of treatment outcomes in the 
management of CLL with different classes of agents in the same population. This will 
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more likely yield more reliable inferences based on true observations, than when different 
outcomes are evaluated in different populations and pieced together. 
Furthermore, our study period captured a baseline period and rapidly transforming 
period in CLL management, our observations captured changes in real-time as they were 
occurring. 
The study used patients’ data from the largest integrated health care system in the 
United States, with a presence in all 50 states, therefore, the study results will be 
generalizable to all veteran hospitals and clinics in the United States. The data used are 
comprehensive, because VHA maintains repositories that include data from both hospital 
and clinic settings. 
Furthermore, the VHA system maintains a vital status file that enables 




Our first limitation in this study is the use of electronic medical record which does 
not contain all information such as relevant prognostic factors, disease staging, molecular 
and genetic aberrations (e.g., presence of Del(17p)/TP53 mutation), and other markers of 
disease severity, which could have influenced treatment choice or survival outcomes. 
Therefore, we are not able to evaluate the effect of all cofounders. 
Secondly, some of the novel therapies regulatory approval were within the study 
period, therefore, only a subset of CLL patients commenced treatment within the study 
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enrolment period, limiting the sample size for analyses for some of the therapies. 
Ibrutinib obtained six approvals for use in CLL during this time period and thus we were 
working in a rapidly changing system. 
The Veterans Health Administration system database is made up of 
predominantly elderly, white, male population, which constitutes our study population 
thus, our findings may not be generalizable to non-VHA settings. 
Finally, there may be variation in the extent of physician reporting of patients' 
comorbidities and adverse effects. In the myriad of combinations of agents used in CLL 
treatment, some of the combinations might be missed, but these are not likely to be 
frontline therapies. 
The use of electronic health records for research purposes is still evolving, and 
because some of these EHR systems are not created primarily for the purpose of research, 
but rather for patient care, they may contain errors, and there is limit to how much 




APPENDIX A  
Table 1. PATIENTS BASELINE DEMOGRAPHICS AND CLINICAL 
CHARACTERISTICS 
Baseline characteristic All 
N 655 
Age (years) N=655, 70 (33-90) 
Age groups -- 
     Missing N=0 
     1=<65 years 159/655=24% 
     2=65-74 years 307/655=47% 
     3=>74 years 189/655=29% 
Male 647/655=99% 
Race  
     Missing N=8 
     1=White 548/647=85% 
     2=Black 92/647=14% 
     3+=Other 7/647=1% 
Charlson score N=655, 2 (0-6) 
Charlson Age score N=655, 5 (1-10) 
Charlson comorbidities -- 
     Congestive heart failure 67/655=10% 
     COPD 144/655=22% 
     Cerebrovascular disease 50/655=8% 
     Dementia 7/655=1% 
     Diabetes (no complications) 218/655=33% 
     Diabetes (with complications) 67/655=10% 
     Hemi/paraplegia 3/655=0% 
     HIV/AIDS 1/655=0% 
     Liver (mild) 42/655=6% 
     Liver (mod/severe; cirrhosis) 4/655=1% 
     Cancer 651/655=99% 
     Metastatic cancer 34/655=5% 
     Myocardial infarction 18/655=3% 
     Peptic ulcer disease 5/655=1% 
     Peripheral vascular disease 51/655=8% 
     Renal disease 85/655=13% 
Additional comorbidities -- 
     Coronary artery disease 82/655=13% 
     Atrial fibrillation 70/655=11% 
     Arrhythmia 86/655=13% 
     Deep vein thrombosis 16/655=2% 
     Pulmonary embolism 23/655=4% 
     Prior bleed 45/655=7% 
     Lung diseases 28/655=4% 
     Intestinal disorders 27/655=4% 
          Crohn’s 0/655=0% 
          GI ulcers 0/655=0% 
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     High uric acid or gout 41/655=6% 
     High cholesterol 43/655=7% 
     Hypertension 154/655=24% 
     Rheumatoid arthritis 10/655=2% 
Agent Orange exposure 58/655=9% 
VA Priority Group -- 
     Missing N=0 
     Group 1 258/655=39% 
     Groups 2-6 279/655=43% 
     Groups 7-8 118/655=18% 
Concomitant medications -- 
     Anticoagulants 205/655=31% 
     Antiplatelets 159/655=24% 
     Antiarrhythmics 270/655=41% 
     CYP3A4 inhibitors 192/655=29% 
     CYP3A4 inducers 307/655=47% 
     Acid reflux 275/655=42% 
     Pain 363/655=55% 
     Anti-hypertensives 349/655=53% 
Geographic region -- 
     VISN1 36/655=5% 
     VISN2 32/655=5% 
     VISN4 27/655=4% 
     VISN5 24/655=4% 
     VISN6 36/655=5% 
     VISN7 32/655=5% 
     VISN8 52/655=8% 
     VISN9 32/655=5% 
     VISN10 38/655=6% 
     VISN12 40/655=6% 
     VISN15 34/655=5% 
     VISN16 43/655=7% 
     VISN17 18/655=3% 
     VISN19 39/655=6% 
     VISN20 31/655=5% 
     VISN21 34/655=5% 
     VISN22 55/655=8% 
     VISN23 52/655=8% 
Laboratory values -- 
     White blood cell count N=598, 59 (1-564) 








Table A2. Outcome Variables for all therapies combined. 
Treatment outcome All 
Timed outcomes, n, median (range), days -- 
     TTFT=Time from dx to initiation N=639, 1164 (0-5793) 
     TIDC=Time from initiation to dc N=655, 212 (0-1644) 
     TIFU=Time from initiation to eofu N=655, 961 (0-1780) 
     TTNT=Time from dc to next tx N=563, 295 (1-1509) 
     OS1=Initiation to death N=217, 740 (9-1833) 
     OS2=Dc to death N=217, 544 (1-1748) 
Outcomes (in 6 months), n/N=% -- 
     Emergency room visits 257/655=39% 
     Urgent care visits 24/655=4% 
     Hospital admissions 200/655=31% 
     Death 17/655=3% 
Outcomes (overall), n/N=% -- 
     Emergency room visits 464/655=71% 
     Urgent care visits 69/655=11% 
     Hospital admissions 434/655=66% 
     Death 217/655=33% 
Complications, n/N=% -- 
     Diffuse large B-cell lymphoma 124/655=19% 
     Hodgkin’s lymphoma 22/655=3% 
     Stem cell transplant 13/655=2% 
     Skin cancer 21/655=3% 
     Lung cancer 21/655=3% 
     Bladder cancer 16/655=2% 














Table B1: Distribution of the Nine Select treatments across the Three lines of Therapies 



























































































Table B2. Yearly Uptake of Nine Select First-line CLL therapies 2014 -2018 
 
Treatment  2014  2015  2016  2017  2018  Total 
BR  67  54  26  15  5  167 
FR/FCR/PCR  38  24  12  12  1  87 
Ibrutinib (+/‐ CD20)  37  39  37  35  20  168 
PI3K inhibitor (+/‐ 
CD20)  0  3  1  0  0  4 
Venetoclax (+/‐ CD20)  0  0  1  1  0  2 
Chlorambucil (‐ CD20)  36  37  24  17  7  121 
CD20 + Chlorambucil  13  19  12  4  2  50 
CD20 mono  15  7  4  5  0  31 
Other  6  5  8  5  1  25 
All novel therapies  37  42  39  36  20  174 










Table B3. Distribution of novel treatments and CT/CIT within the lines of therapy 
 
Therapy 1L (N=655) 2L (N=953) 3+L (N=1372) 
NA 174 (27%) 655 (69%) 527 (34%) 











































































































































































Table C1. Overall Survival at 6 months post treatment initiation. 
Therapies Survival in 6 months P-value  
BR 164/167 (98%) 0.464 
FR/FCR/PCR 85/87(98%) 0.7369 
IBRU 160/165 (95%) REF 
PI3K 4/4 (100%) 1 
VEN 2/2 (100%) 1 
CHLOR 120/121 (99%) 0.199 
CD20+CHLOR 50/50 (100%) 0.593 
CD20 MONO 31/31 (100%) 1 
OTHER 22/25 (88%) 0.037 
CT/CIT  472/481 (97%)   



























Table D1. Mean (range: Low and High)) Charlson Age score for patients alive and Dead 
at 6 months. 
 




OTHER IBRU P13K VEN NA CT/CIT ALL 
LOW 1 1 1 3 3 1 1 2 6 1 1 1 
HIGH 8 9 8 8 6 7 9 6 6 9 9 9 
MEAN 4 4 5 5 5 4 5 4 6 5 4 5 
 




OTHER IBRU P13K VEN NA CT/CIT ALL 
LOW 1 2 3 4 3 3 3 5 5 3 1 1 
HIGH 8 10 9 9 9 8 9 5 5 9 10 10 














 N OS1 [range] STDev N OS1 [range] STDev P-value  
Overall 153 782(9-1833) 444 64 640(33-1652) 434 0.031  
Low (1-3) 28 829(176-1833) 446 8 892(158-1500) 552 0.7736  
Moderate- 
High (4-7) 
114 788(115-1739) 443 50 607(51-1652 394 0.0106  
Very High 
(≥8) 
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